



Published in final edited form as:

J Genet Syndr Gene Ther. 2011 June 30; 2(104): .

Epigenetics in Developmental Disorder: ADHD and Endophenotypes

Trevor Archer¹, Marlene Oscar-Berman², and Kenneth Blum^{3,*}

¹Department of Psychology, University of Gothenburg, Box 500, SE-40530 Gothenburg, Sweden

²Departments of Psychiatry, Neurology, and Anatomy & Neurobiology, Boston University School of Medicine, and Boston VA Healthcare System, Boston, MA, USA

³Department of Psychiatry, University of Florida College of Medicine, and McKnight Brain Institute, Gainesville, FL, USA

Abstract

Heterogeneity in attention-deficit/hyperactivity disorder (ADHD), with complex interactive operations of genetic and environmental factors, is expressed in a variety of disorder manifestations: severity, co-morbidities of symptoms, and the effects of genes on phenotypes. Neurodevelopmental influences of genomic imprinting have set the stage for the structural-physiological variations that modulate the cognitive, affective, and pathophysiological domains of ADHD. The relative contributions of genetic and environmental factors provide rapidly proliferating insights into the developmental trajectory of the condition, both structurally and functionally. Parent-of-origin effects seem to support the notion that genetic risks for disease process debut often interact with the social environment, i.e., the parental environment in infants and young children. The notion of *endophenotypes*, markers of an underlying liability to the disorder, may facilitate detection of genetic risks relative to a complex clinical disorder. Simple genetic association has proven insufficient to explain the spectrum of ADHD. At a primary level of analysis, the consideration of epigenetic regulation of brain signalling mechanisms, dopamine, serotonin, and noradrenaline is examined. Neurotrophic factors that participate in the neurogenesis, survival, and functional maintenance of brain systems, are involved in neuroplasticity alterations underlying brain disorders, and are implicated in the genetic predisposition to ADHD, but not obviously, nor in a simple or straightforward fashion. In the context of intervention, genetic linkage studies of ADHD pharmacological intervention have demonstrated that associations have fitted the “drug response phenotype,” rather than the disorder diagnosis. Despite conflicting evidence for the existence, or not, of genetic associations between disorder diagnosis and genes regulating the structure and function of neurotransmitters and brain-derived neurotrophic factor (BDNF), associations between symptoms-profiles endophenotypes and single nucleotide polymorphisms appear reassuring.

Keywords

Epigenetic; Regulation; Domain; Parent-of-origin; Dopamine; Serotonin; Noradrenaline; Brain-derived neurotrophic factor; Intervention; Endophenotypes

Copyright: © 2011 Archer T, et al.

*Corresponding author: Kenneth Blum, PhD, Department of Psychiatry, University of Florida College of Medicine, and McKnight Brain Institute, 100S Newell Drive, Gainesville, FL, 32610. USA, Tel: 619-890-2167; Fax: 619-236-3316; drd2gene@aol.com.

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Introduction

Attention-deficit/hyperactivity disorder (ADHD) is distinguished by several highly heterogeneous aspects. It is caused by a multitude of interactive neurobiological and environmental factors operating in a highly complex manner. The consequences of multiple gene interactions with environment and each other through complex mechanisms, such as genetic heterogeneity or polygenicity, with phenotypic variability has contributed to marked individual differences in the manifestation, severity and comorbidity of symptoms in neuropsychiatric and developmental disorders [1–3]. Genetic heterogeneity, allelic or locus, is a phenomenon through which a single phenotype or genetic disorder may be caused by any one of many alleles or non-allele mutations, independently, in contrast to pleiotropy whereby a single gene may cause multiple phenotypic expressions or disorders [4]. Polygenicity refers to the effect by which different genes contribute to a phenotype in concerted action with no main gene effect, or the affect of many genes upon a trait, e.g., the concerted actions of genes in drug sensitization, withdrawal, drug metabolism, and comorbidity [5–6]. Bilateral inheritance in the “hyperactive child syndrome” was presented as evidence of polygenicity almost four decades ago [7]. The vast heterogeneity in ADHD, with consequential complex etiology, is expressed in a variety of genetic, functional, and biomarker domains. Clinical heterogeneity is a consequence of frequent associations with different co-morbidities and dysregulations in psychosocial and operational functioning. Gene-environment interactions, the basis of epigenetics, may modify the expression of individuals’ genetic background by either strengthening or weakening the effects of genes on phenotypes [8] with particular relevance in psychopathology [8]. Pennington et al. [9] reviewed evidence for gene-environment interactions, in opposite directions, in ADHD and reading disability (diathesis stress in the former and bioecological in the latter). Epigenetic mechanisms that contribute to several neuropsychiatric disorders [10] and previously considered stable and irreversible conditions, have been shown to be dynamic and may be reversible, even in fully differentiated brain cells [11–13].

Steinhausen [14] has reviewed certain aspects of the disorder pertaining to: (a) selected etiological domains that involve the influences of genes, brain regions, and functions in the interactions of causal factors, and (b) the clinical heterogeneity encompassed in comorbidity, gender effects, and intervention-outcome. In view of the interaction of genotype with psychosocial factors, the identifications of environmental mechanisms and gene combinations is limited by paucity of candidate environments and gene markers as yet to be studied [15]. Wong et al. [16] measured quantitatively DNA methylation across the promoter regions of the dopamine receptor 4 gene (DRD4), the serotonin transporter gene (SLC6A4/SERT), and the X-linked monoamine oxidase A gene (MAOA) through application of DNA sampled in 46 MZ twin-pairs and 45 DZ twin-pairs (total n=182) at the ages of 5 and 10 years. The data suggested that DNA methylation differences are apparent already in early childhood, even between genetically identical individuals, and that individual differences in methylation are not stable over time. This longitudinal-developmental study suggested that environmental influences are important factors accounting for inter-individual DNA methylation differences, and that these influences differ across the genome [but see also 17].

Epigenetics, inherited changes in phenotype or gene expression caused by mechanisms other than changes in the underlying DNA sequence (involving modifications of the activation of certain genes, but not the basic structure of DNA), is implicated in developmental origins of chronic noncommunicable disease [18,19]. 5-methyl cytosine with its role in controlling gene expression and the pattern of methylation is supported by much data that methylation is strongly associated with gene silencing in a variety of biological contexts, the role of chromatin and histone modifications, and the influence of regulatory RNAs [20,21].

Epigenetic regulation may be mediated by DNA methylation, physical changes to chromatin structure, and the action of siRNA molecules (cf. [22]). Between the stage of the embryo and adulthood, several developmental spurts occur in the brain during which activity and proper nutrition facilitate full brain capacity for synaptogenesis and neurogenesis. Malnutrition and adversity underlie the ‘gene-switching’ over lifetime: gene-switches are positive with adequate social bonding and good nutrients, but negative with shock/trauma, stress, or poor nutrition [23]. Marked neurodevelopmental influences of genomic imprinting set the stage for structural-physiological variation that affect cognition, emotion, and pathophysiology of ADHD (e.g., [24]). Nevertheless, although innumerable gene association studies have provided a huge amount of evidence for multi-involvement for neurotransmitters and metabolic enzymes (e.g., monoamine oxidase [MAO] or tryptophan hydroxylase [TPH]) in genetic predispositions for the disorder, the conflicting results, due to failure to obtain association, are rife [25–27].

Environmental Influences

The contributions of adverse environmental insults to potential risk for childhood and life-cycle disorders have been shown to be widespread [28–32]. The time of introduction of insult, e.g., prenatal, is of particular importance [33–35]. Adversity during periodic catastrophes caused by war and/or disease also has offered a recurrent environmental malefactor [36]. Both prenatal and postnatal stress may exert adverse effects on the brain development that are expressed in cognitive, motor, and emotional domains during childhood, adolescence, and adulthood [37–39]. For example, prenatal maternal stress induced alterations in the behavior of their offspring through elevated levels of corticotrophin-releasing hormones and consequent disruptions in the normal functioning of the hypothalamic-pituitary-adrenal axis [40,41]. It should be noted that the HPA axis alterations are implicated in a variety of postnatal disorders involving the actions of adrenal glucocorticoids [42,43]. Intrauterine growth retardation (IUGR) can reset permanently the HPA axis [44,45], the reprogramming of which may involve persistently altered expression of the hippocampal glucocorticoid receptor (hpGR); dysregulation at this site is linked to increased axis reactivity (cf. [46]) Environmental exposure to a wide variety of agents, characteristically disruptive, has been found to invoke epigenetic processes that affect the developmental trajectories in a generally detrimental manner [48–53]. The epigenetic state of an organism (or “epigenome”) incorporates a landscape of complex and plastic molecular events that may underlie the missing link that integrates genotype with phenotype [54]. Through DNA methylation, histone modifications, and small regulatory RNAs, the epigenome systematically controls gene expression during development, both *in utero* and throughout life. Animal model studies have demonstrated that induction and stability of induced changes in the phenotype of the offspring involve altered epigenetic regulation by DNA methylation and covalent modifications of histones. In turn, opportunities arise for the induction of differential risk of non-communicable diseases in humans by variation in the quality of the early life environment. Burdge and Lillycrop [55] have shown that such epigenetic changes are highly gene specific and function at the level of individual CpG dinucleotides. This was seen through interventions applying the supplementation with folic acid or methyl donors during pregnancy, or folic acid after weaning, which alter the phenotype and epigenotype induced by maternal dietary constraint during gestation. CpG sites are regions of DNA where a cytosine nucleotide occurs next to a guanine nucleotide in the linear base sequence along its length. CpG is shorthand for “—C—phosphate—G—”, that is, cytosine and guanine separated by a phosphate, which links the two nucleosides together in DNA. The “CpG” notation is used to distinguish this linear sequence from the CG base-pairing of cytosine and guanine (e.g., [56]). Through epigenetics the methylation of the cytosine within a gene can turn the gene off. Burdge and Lillycrop [55] describe the

mechanism that underlies the early life origins of disease and to place these studies in a broader life-course context (see also [57,58]).

Metastable epialleles, sensitive to environmental influences such as diet, undergo molecular changes that, once established, remain for the life of the individual [59]. These modifications are epigenetic, and in some cases they may survive across generations, that is, through meiosis. This is termed transgenerational epigenetic inheritance. Metastable epiallele genes are variably expressed in genetically identical individuals due to epigenetic modifications established during early development [60]. Maternal nutrition and environment have been shown to affect metastable epiallele methylation patterns and subsequent adult phenotype. Dolinoy et al. [61] observed variable histone patterns in the 5' long terminal repeat (LTR) of the murine viable yellow Agouti (A(vy)) metastable epiallele. The observed region contains 6 CpG sites, which are variably methylated in isogenic A(vy/a) offspring. Yellow mice, which are hypomethylated at the A(vy) LTR and exhibit constitutive ectopic expression of agouti (a), displayed also enrichment of H3 and H4 diacetylation. Pseudoagouti mice, in which A(vy) hypermethylation, considered to silence ectopic expression, displayed enrichment of H4K20 tri-methylation. Bernal and Jirtle [62] found that using the Agouti viable yellow (A(vy)) mouse model, dietary BPA exposure was shown to hypomethylate both the A(vy) and the Cabp(IAP) metastable epialleles. This hypomethylation effect was counteracted with dietary supplementation of methyl donors or genistein. Epigenomes present reactive systems with lability allowing reception and response to environmental perturbations, thereby ensuring survival during fetal growth. Adverse environments may impose through genotoxic and epigenotoxic effects on the population gene-pooled genome. This type of genetic pliability may lead to aberrant epigenetic modifications that persist into later life and induce numerous disease states. They suggest that epigenotoxicity could lead to numerous developmental, metabolic, and behavioral disorders in exposed populations, whereby the heritable nature of epigenetic changes also increases the risk for transgenerational inheritance of phenotypes [62]. Bell et al. [63] have examined genotype-epigenotype interactions in the context of Type 2 Diabetes (T2D), focussing on known regions of genomic susceptibility. They identified increased DNA methylation on the FTO obesity susceptibility haplotype, tagged by the rs8050136 risk allele A ($p = 9.40 \times 10^{-4}$, permutation $p = 1.0 \times 10^{-3}$). Sequence level analysis, followed by pyrosequencing validation, revealed that the methylation difference was driven by the coordinated phase of CpG-creating single nucleotide polymorphisms (SNPs) across the risk haplotype. This 7.7 kb region of haplotype-specific methylation, encapsulates a "highly conserved non-coding element," previously validated as a long-range enhancer, and supported by the histone H3K4me1 enhancer signature. Taken together, these results displayed the integration of genome-wide association SNP and epigenomic DNA methylation data can identify potential novel genotype-epigenotype interactions within disease-associated loci. In short, environmental influences may be adverse (above) or benign (e.g. the role of physical exercise) in discussing the epigenetics of a developmental disorder, such as ADHD, an attempt is made to seek associations between adverse environments and genetic configurations with endophenotypes (disorder symptoms) rather than the diagnosis itself.

Epigenetics in ADHD

In the etiopathogenesis of ADHD, environmental insults that contribute to adverse risk factors have been documented amply [64–67]. Incidence analyses, including meta-analysis studies, have indicated that the world-wide prevalence of ADHD may well be in excess of 5% [68–70], with astronomical social and economic costs [71]. Gustafsson and Källén [72] reported that the results of a multiple logistic regression analysis indicated that ADHD was significantly associated with several environmental factors: a young maternal age, maternal

smoking, maternal birthplace in Sweden, and preterm birth <weeks, as well as a male predominance. Wallis et al. [73] have reviewed several notions that are required for sufficient consideration of ADHD genetics, these included: (a) the complexities involved, (b) evidence for a primarily genetic component, (c) evidence that there exist only a few genes with major effects, (d) identification of the best candidate genes, and (e) descriptions of gene-environment interactions, or the essential basis of epigenetics. As the specificity (or lack of) of genes, phenotypic effects and risk factors unfolds, it will be observed that these notions both verified and contradicted. However, chromosomal regions containing potential ADHD predisposing loci, some overlapping in two or more studies, including 5p, 6q, 7p, 11q, 12q, and 17p, have been identified through family-based linkage studies (cf. [74]). Confirmed association of ADHD with several candidate genes, e.g., DAT1, DRD4, SNAP5, 5HTT, HTR1B, and DBH, was reported several years ago [75], but also see [74]. For example, Forero et al. [76] performed a meta-analysis study aimed at eight common variants located in five top candidate genes, all implicated in synaptic transmission and plasticity, for ADHD (brain-derived neurotrophic factor [BDNF], HTR1B, SLC6A2, SLC6A4, and SNAP25). They observed a weak but significant association with a SNP located in the 3' UTR region of the SNAP25 gene (synaptosomal-associated protein 25, rs3746544, T allele). At glutamatergic synapses SNAP-25 decreases the Ca²⁺ responsiveness.

Developmentally, the disorder is characterized by behavior hyperactivity, attentional and concentration problems, and impulsiveness, and there is only a rudimentary understanding of the etiology. Nevertheless, the relative contributions of genetic and environmental factors provide rapidly proliferating insights into the developmental trajectory of the condition, both structurally and functionally [77–79]. Cook et al. [80] described a genetic association between ADHD and the 10 repeat allele of a variable number of tandem repeat (VNTR) polymorphism within the 3'-untranslated region of the dopamine transporter gene (DAT1: SLC6A3). Epigenetic factors provide a myriad of possibilities for disorder susceptibility concerning a broad spectrum of neuropsychiatric conditions, including ADHD [38,81,82]. Mill and Petronis [83] have described the associations between early developmental insults and ADHD that arise from epigenetic dysregulations. They proposed that the elucidation of the processes linking specific environmental pathogens to the eventual expressions of the disorder will uncover avenues for preventative and therapeutic intervention [84]. Das et al. [85] have studied the interaction between ten functional polymorphisms in DRD4, DAT1, MAOA, COMT, and DBH genes were explored in the Indo-Caucasoid population. Case-control analysis revealed higher occurrence of DAT1 intron 8 VNTR 5R allele in cases; significant preferential transmission of the 7R-T (DRD4 exon3 VNTR-rs1800955) and 3R-T (MAOA-u VNTR-rs6323) haplotypes were obtained from parents to probands. Gene-gene interaction analysis revealed significant additive effect of DBH rs1108580 and DRD4 rs1800955 with significant main effects of DRD4 exon3 VNTR, DAT1 3'UTR and intron 8 VNTR, MAOA u-VNTR, rs6323, COMT rs4680, rs362204, DBH rs1611115 and rs1108580, thereby pointing towards a strong association of these markers with ADHD. Correlation between gene variants, high ADHD score, and low DBH enzymatic activity was noticed also, especially in male probands.

Association studies in ADHD offer conflicting data [86–91]. Kebir et al. [92] identified 29 studies that examined 10 genes (DRD4, DAT1, COMT, DBH, MAOA, DRD5, ADRA2A, GRIN2A, BDNF, TPH2) in relation to neuropsychological traits (endophenotypes) that were relevant for ADHD, in this case with difficulties involving Continuous Performance Test variables. Their most consistent result involved the association of high reaction time variability with the 7-repeat allele absence specific to ADHD, and the 10-repeat homozygosity. The authors outlined several methodological issues and confounding factors that have bedevilled reliable conclusions. These included measurement errors, developmental alterations in cognitive abilities, gender, psychostimulant effects, and the

presence of co-morbid conditions. Nevertheless, Brookes et al. [93,94] have shown association between ADHD and allele 6 of a VNTR mapped to intron 8, DNA region within a gene that is not translated into protein, of DAT1. Non-coding intron sections are transcribed to precursor mRNA (pre-mRNA) and some other RNAs (such as long noncoding RNAs), and subsequently removed by a process called splicing during the processing to mature RNA. After intron splicing (i.e., removal), the mRNA consists only of exon derived sequences, which are translated into a protein [95]. Other studies have presented more-or-less confirmatory results [96,97].

Parent-of-Origin Effects

In the light of family, adoption, and twin studies, it is apparent that a number of genetic mechanisms are implicated, one of which is *genomic imprinting*. The transmission of abnormalities has been shown to be dependent upon the sex of the parent from whom they are inherited. Genomic imprinting may occur by one parent “marking” a gene by DNA methylation, through addition of a carbon (methyl group) to the DNA base, to indicate how their gene is to be used. Parent-of-origin effect offers a general notion that describes two distinctive phenomena: parent-of-origin effects on *transcription* and parent-of-origin effects on *mutation rates*. A parent-of-origin effect on transcription, or genomic imprinting, results from epigenetic modification of the genome which, in turn, results in unequal transcription of parental alleles [98]. In imprinted genes, one allele is silenced according to its parental origin, and imprinted traits are, in turn, passed down the maternal or paternal line [99]. In a study of parent-of-origin effects in ADHD, Goos et al. [100] investigated 60 children with maternal-only history of ADHD and 131 children with paternal-only history of ADHD. The children were compared on three domains for which prior evidence suggested parent-of-origin effects might exist: core symptoms, disruptive behavior, and depression. It was shown that the maternal history group received higher ratings of behavior disorder (ADHD, conduct disorder [CD], and oppositional symptoms) than the paternal history group. They observed also parent-of-origin effects for depression, with the paternal-only history group rating themselves as significantly more depressed than children in the maternal-only history group, in particular the girls. According to their account, elevated paternal transmission, relative to maternal, implied genomic imprinting, and the interaction with proband sex indicated the involvement of the sex chromosomes or sex-specific physiological or hormonal factors. There is accumulating support for the notion that genetic risks for neuropsychiatric disorders often interact with the social environment, the parental environment in infants and young children. In order to increase understanding of gene-environment interactions involving early parenting, Lahey et al. [101] tested interactions between maternal parenting and the VNTR polymorphism in the 3' untranslated region of the dopamine transporter gene of children. A 9-year longitudinal study of 4-6-year-old children meeting criteria for ADHD and demographically matched controls was carried out. The researchers obtained a significant inverse relation between levels of both positive and negative parenting at 4–6 years and the number of later symptoms of CD, but mainly among children with two copies of the 9-repeat allele of the VNTR.

Parent-of-origin effects and risk for ADHD have been investigated with much attention to detail, cf. [102], although here too evidence is conflicting [103–106]. Hawi et al. [107] examined the parent-of-origin effect at DAT1 (paternal over transmission of ADHD-associated alleles) in three independent samples consisting of Irish Sample 1 (178 ADHD nuclear families), Irish Sample 2 (52 trios in a sample of 108 nuclear families of children with ADHD), and English Sample (63 parent-proband trios and 44 mother-child duos), providing a total of 1248 ADHD nuclear families. They have reported paternal over-transmission of risk alleles in some ADHD-associated genes. An IMAGE sample provided strong support for a parent-of-origin effect for allele 6 and the 10 repeat allele (intron 8 and

3'UTR VNTR, respectively). Their findings thereby lend support for the phenomenon of paternal over-transmission of the DAT risk alleles. Hawi et al. [104] reported a systematic over-transmission of paternal alleles at candidate genes associated with ADHD. For the nine genes included in their analysis, the overall odds ratio for paternal transmission was 2, compared with 1.3 for maternal transmission (paternal vs. maternal $\chi^2=9.6$; $p=.0019$). It was concluded that transmission to female participants from either parent, was significantly stronger than to males. Notwithstanding, the paternal over-transmission effect has been documented [97,108].

The notion of endophenotypes that are markers of an underlying liability to psychiatric disorders may facilitate detection of genetic risks relative to a complex clinical disorder, such as ADHD [109–111], and motor response inhibition offers a prime candidate endophenotype in ADHD. Certain behavioral symptoms can be characterized as stable phenotypes with a clear genetic connection: inheritable, state-dependent disorders whereby endophenotype and illness co-segregate within families. For example, siblings of ADHD probands, while not behaviorally expressing the disorder, present ADHD-associated deficits in response inhibition [112,113]. Goos et al. [114] studied covariation in inhibitory control and differential covariation as a function of parental sex in children with ADHD, unaffected siblings, and their biological parents by applying several validity criteria for inhibitory control as an endophenotype, including sensitivity to the disorder and presence in unaffected relatives. They obtained inhibitory control deficits in children with ADHD as well as in their parents, independent of symptom severity in both generations: inhibitory control ability in children was significantly predicted by the ability of their parents, particularly their fathers. They concluded that inhibitory control deficit is a cognitive marker of genetic risk shared by parents and offspring and that endophenotype notion pertains to differential parental contributions to this risk. This observation is consistent with findings of parent-of-origin effects in the transmission of certain risk alleles observed in molecular analyses [115]. Wood and Neale [116] described the utility of twin studies as an important research tool in the development of endophenotypes, defined as alternative, more highly heritable traits that act at earlier stages of the pathway from genes to behavior.

Hill et al. [117] indicated that the intron 8 VNTR is a functional variant with an ADHD susceptibility allele having reduced activity (see also [93,118,119]). Joobert et al. [120] presented findings that support a role for the DAT gene 3'-UTR VNTR polymorphism in modulating the response of some behavioral dimensions to methylphenidate in children with ADHD. Further, investigating $G\alpha_{olf}$ gene GNAL involvement in ADHD, Laurin et al. [121] studied the inheritance pattern of 12 GNAL polymorphisms in 258 nuclear families ascertained through a proband with ADHD (involving 311 affected children). The G_8 -like subunit $G\alpha_{olf}$ is expressed in D_1 -rich brain regions involving D_1 and D_5 receptor mediation of adenylyl cyclase activation. Their categorical analysis of individual marker alleles demonstrated biased transmission of one polymorphism in GNAL intron 3 (rs2161961) that was associated with inattention and hyperactivity/impulsivity. They found also a strong maternal effect with preferential transmission of maternal alleles for rs2161961A and rs8098539A.

Neurotransmitters

Dopamine-Regulating Genes in ADHD

Early adverse stress trauma environments are implicated in ADHD over national boundaries [122–124]. Deprivation in social and environmental conditions may perturb early cellular patterns of neurodevelopment that are manifested as disorder expression in later life [125], with aspects of ADHD originating in early deprivation [126,127]. Epigenetic factors have implicated both dopamine and serotonin in ADHD symptoms, particularly impulsive

behaviors. For example, functional gene variants in the serotonin transporter gene-linked polymorphic region 5-HTTLPR are implicated in neural mechanisms of disorders relating to impulsive control [128,129]. Moreover, candidate gene studies in ADHD children have had a predominating focus upon the monoaminergic neurotransmitter systems with particular attention on dopamine and the major focus upon DAT1 and the DRDs dopamine receptor genes. Early institutional deprivation with ADHD as outcome [130] was shown to vary greatly over individuals despite high levels of adversity [131]. Perinatal environmental risk is moderated by genetic factors in determining outcome [132,133]. The DAT1 (SLC6A3) transport and DRD4 receptor genes are implicated in the pathophysiology of ADHD [83,134,135]. Stevens et al. [136] examined the moderating effect of DRD4 and DAT1 functional polymorphisms on deprivational influences following institutionalization upon ADHD in a longitudinal study with participants at ages 6, 11, and 15 years-of-age. This type of study would ensure both a proper establishment of a $G \times E$ hypothesis, and a test of developmental $G \times E$ mechanisms. The investigators observed that the early institutional-deprivation as an ADHD risk factor was moderated by the DAT1 but not the DRD4 genotype. These effects appeared first in early-adolescence and persisted to mild-adolescence, which was their ultimate period of analysis. The authors concluded that the results: (a) provided evidence for developmental continuities in the $G \times E$ interaction, (b) explained part of the heterogeneity in ADHD outcomes following institutional deprivation, and (c) further contribute to understanding of environmental determinants of ADHD in the institutional setting. In a broader perspective, their findings provide an essential description of the developmental trajectories to be defined in developmental disorder.

Following the initial report by Comings et al. [137] of Taq A1 allele association in ADHD individuals, and as Blum et al. [74] have reviewed, both positive and negative findings related to the putative association of DRD2 A1 allele as a critical gene polymorphic link to ADHD and related behaviors are documented (see also [138,139]). Plausible evidence for the ADHD association is derived from a number of studies. For example, Sery et al. [140] obtained statistically different genotypic and allelic frequencies of DRD2 polymorphism between the two groups of boys that they studied. Similarly, Kopeckova et al. [88] observed that ADHD-risk (a) was linked to a risk allele in DRD2 gene, the 5-HTT gene, and the DAT1 gene, (b) was elevated at homozygotes for risk alleles in the same genes and for polymorphisms G444A and C1603T in dopamine- β -hydroxylase (DBH), and (c) was increased in the presence of allele DBH +444A and allele DBH +1603T. More recently, Paclt et al. [141] studied a sample of 269 ADHD boys and a control group of 317 boys. Comparison of genotype frequencies indicated a highly significant difference between the two groups, with the A1 allele having a 4.359-fold higher risk for ADHD. Within the context of association studies focused upon endophenotype, Esposito-Smythers et al. [142] found interaction effects between the DRD2 TaqIA polymorphism and CD, also between A1+ status and impulsiveness, whereby adolescent carriers of the A1 allele with CD or impulsiveness, reported higher levels of problematic alcohol use than non-carriers (A2/A2 or A1-). They obtained the same interaction effect between impulsiveness and DRD2 TaqIA polymorphism regarding severity of problem drug use. However, no interaction effects were obtained between the DRD2 allele status and ADHD on severity of problem drinking or drug use. Blum et al. [74] discussed the viability of ADHD genetic testing at birth with obvious diagnostic benefits probable via: (a) coupling of genotyping with psychometric instruments, (b) that dopaminergic genotyping to determine high risk future substance abuse may affect use in adolescents, and (c) applications of D2 agonists for ADHD symptoms related to specific candidate polymorphisms. Following several independent meta-analyses confirming the association of DRD2 polymorphisms with impulsive-addictive-compulsive behaviors that include ADHD symptoms, Blum et al. [143,144] coined the notion of "Reward Deficiency Syndrome" implicating dopamine D2 gene variants (see also [145–147]).

It is known that an adverse prenatal environment, e.g., intrauterine growth retardation (IUGR), elevates the risk for negative neurobehavioral developmental outcomes, affecting for example approximately 10% of all US infants, a known risk factor for ADHD [148,149]. Nutritional deprivation offers another disease sharing pathophysiological expressions with the disorder particularly with respect to impulsiveness [150]. In a mouse model of ADHD, Vucetic et al. [151] fed mouse dams on a protein deficient (8.5% protein) or isocaloric control (18% protein) diet through pregnancy and lactation (a well validated rodent model of IUGR), and then studied dopamine-related gene expression, dopamine content, and behavior in adult offspring. IUGR offspring displayed a six to eightfold overexpression of dopamine-related genes (tyrosine hydroxylase and dopamine transporter) in brain regions related to reward processing, i.e., ventral tegmental area, nucleus accumbens, prefrontal cortex, and hypothalamus, as well as increased number of TH-ir neurons in the ventral tegmental area and increased dopamine in the prefrontal cortex. It was found too that methylation of the promoter region of Cyclin-dependent kinase inhibitor 1C, critical for dopaminergic neuron development, was decreased by half and there was a resultant two to sevenfold increase in its expression across brain regions. Prenatal dietary-restricted animals showed endophenotypes similar to ADHD symptoms.

Variations in the catechol-O-methyltransferase (COMT) gene, which encodes for the enzyme, affect functioning in the prefrontal region more markedly than other regions. The COMT genotype has been shown to influence prefrontal dopaminergic activity cognitive expressions in children and adolescents [152,153]. The COMT gene has been associated with phenotypic variation among ADHD children with the Val/Val homozygote presenting symptoms of conduct disorders, aggressivity, and criminal acts [154]. Nobile et al. [155] studied the association of the functional Val158Met COMT polymorphism and socioeconomic status with CD, oppositional defiant disorder (ODD), and ADHD in a general population sample of 575 Italian pre-adolescents aged 10 to 14 years. They obtained a significant COMT \times Socioeconomic Status interaction with ADHD problems and higher scores among children with Val/Val COMT genotype and low socioeconomic status. There was a significant association of socioeconomic status, ADHD, and CD problems. Thus, socioeconomic status appears to offer a notable environmental factor. In a study of gene-environment interaction effects on autism spectrum symptoms in ADHD children (aged 5 to 17 years), Nijmeijer et al. [156] found that the COMT Val/Val genotype interacted with maternal smoking during pregnancy by elevating stereotypy.

Discordant DNA methylation patterns in adolescent or adult MZ twin pairs have shown that the epigenome is in constant drift over the life course in response to stochastic and environmental factors, but in infancy the situation appears 'prehensile'. Several features of neuropsychiatric disorders, such as ADHD, are consistent with an epigenetic dysregulation, including discordance of monozygotic twins, late age of onset, parent-of-origin and gender effects, and fluctuating disease course have permitted insights regarding the epigenome and its role in maintenance of normal genomic functions, as well as disease etiopathogenesis [157]. Ilott et al. [158] have reported heritability and genetic association between specific risk alleles and ADHD symptom expressions in a population of 2-year-old twins showing modest evidence for DAT1 and NET1. In order to ascertain extent of additive genetic variance influence on symptoms, Ilott et al. [158] studied 312 pairs at age-points, 2 and 3 years. It was found that at these age-points ADHD symptoms were highly heritable ($H^2 = 0.79$ and 0.78 , respectively) but with significant level of genetic change from the 1st to the 2nd age-point, modest non-shared environmental influence. They obtained also association signals in DAT1 and NET1, with specific effects of 5-HTT and DRD4 at three-years-of-age (see also [158,159]).

Several studies have focussed on dopamine and serotonin candidate genes' association with impulse control. Ha et al. [160] evaluated the influence of 5-HTTLPR and dopamine receptor D4 (DRD4) polymorphisms and their interaction with performance on the Iowa Gambling Task (IGT) in 159 genotyped subjects. After controlling for gender, age, and impulsiveness, they observed no main effects of 5-HTTLPR and DRD4 gene polymorphisms on total IGT score. Nevertheless, there was a significant effect on the interaction between 5-HTTLPR and DRD4 on total IGT score. In the presence of the 5-HTTLPR S'S' (SS+SL(G)+L(G)L(G)), subjects with the DRD4 2R+ (2 repeat carrier) had higher total IGT scores compared to those with the DRD4 2R-. In contrast, in the absence of the 5-HTTLPR S'S', subjects with the DRD4 2R- had a higher total IGT score than those with the DRD4 2R+. Following division of IGT scores into the first and second half of the trials, the 5-HTTLPR by DRD4 interaction effects were stronger in the second half block (decision under risk) than in the first half block (decision under ambiguity). The authors concluded that the DRD4 genotypes might influence decision-making performance differently according to the background genotypes of 5-HTTLPR thereby modulating the expression of impulsivity in decision-making. However, there are studies that have failed to obtain associations with the disorder. Mick et al. [161] failed to identify an association with the val66 allele in BDNF, the COMT-I allele, or the HTTLPR short allele.

Serotonin-Regulating Genes in ADHD

The serotonergic system is critically involved in physiological functions [162], neuropsychiatric disorders [163,164], and regulation of cognitive-emotional functioning [165,166] unsurprisingly, serotonin genes have been strongly associated with cognitive-emotional profiles burdened by impulsiveness. For example, Szily et al. [166] showed that the s-allele of the serotonin transporter gene is associated with a vulnerable cognitive style related to the appraisal of negative emotions. The association of serotonin-influencing genes with impulsivity symptoms of ADHD has received some support [167–172], but yet several investigations have failed to obtain any links [173–175]. Impulsiveness, a heterogenous endophenotype [176] and cardinal symptom of ADHD [177], is expressed in a multitude of neuropsychiatric disorders and comorbidities [178–182]. The serotonin HTR1A gene is located on the long arm of chromosome 5 (6q11.2–13) with the functional C(–1019) G polymorphism (rs6295) a common SNP in the promoter region of the gene [183]. The C(–1019)G functional polymorphism (rs6295) has been suggested to regulate the 5-HT(1A) receptor gene (HTR(1A)) expression in presynaptic raphe neurons, namely, increased receptor concentration and reduced neuronal firing could be associated with the G allele [184]. However, although the putative association between C(–1019)G functional polymorphism and personality traits such as neuroticism and harm avoidance, linked with impulsivity, was observed in carriers of the G allele compared with carriers of the C allele [185], several studies have failed to do so, or for other expressions of neuropsychiatric emotionality [186–188]. Despite this, Benko et al. [189] studied the relationship between HTR1A C(–1019) G polymorphism and impulsiveness in 725 healthy volunteers. They obtained significant differences between the C(–1019)G genotype groups (GG vs. GC vs. CC) whereby subjects carrying the GG genotype expressed more impulsiveness than GC or CC carriers.

The uncertain nature of the link between ADHD and serotonin polymorphisms may be illustrated: Li et al. [190] studied the association between adolescent behavior outcome in ADHD and serotonin pathway genes, including the –1438A>G polymorphism of the serotonin 2A receptor gene (HTR2A) and the –759C>T polymorphism of the serotonin 2C receptor gene (HTR2C). The former, –1438A>G polymorphism, was shown to be related to remission in ADHD, especially functional remission. Similarly, Li et al. [191] found that the T allele of the 83097 C>T polymorphism of HTR4 (serotonin 4 receptor gene) showed a

tendency for preferential transmission to probands with ADHD, and that the C/G haplotype of the 83097 C>T and 83198 A>G polymorphisms, the C/G/C haplotype of these and the -36 C>T polymorphism were under-transmitted to probands with ADHD. Contrastingly, Li et al. [192] examined five variants in three serotonin genes (those coding for serotonin receptors 2A (HTR2A), 5A (HTR5A) and 6 (HTR6)) in a relatively large sample of ADHD nuclear families. Their results did not support any role for these serotonin genes in ADHD. As Kuntsi et al. [193] have argued, it is possible that the real strength of the observed/non-observed associations may be underestimated in certain studies, lacking sufficient consideration of linkage disequilibrium, allelic heterogeneity, population differences, and gene by environment interactions. Ribases et al. [194] analyzed SNPs for 19 serotonin genes from a clinical sample of 451 ADHD patients (188 adults and 263 children) and 400 controls using a population-based association method. They obtained several significant associations: (a) the DDC gene was strongly associated with both adult and childhood ADHD (DOPA decarboxylase (DDC) is an enzyme involved directly in the synthesis of dopamine and serotonin, and indirectly in the synthesis of noradrenaline); (b) the MAO_B gene was found specifically associated in the adult ADHD sample; and (c) the 5HT2A gene showed evidence of association only with the combined ADHD subtype both in adults and in children. Their findings supported the notion of a serotonergic system contribution to the genetic predisposition for ADHD. Additionally, Landaas et al. [195] found a modest association for functional promoter polymorphism, 5-HTTLPR, with 448 adult ADHD patients and 580 controls from Norway. In the context of serotonin and impulsive behavior, Roiser et al. [196] indicated that the less active S allele of the serotonin transporter 5HTTLPR polymorphism was linked to elevated sensitivity to probability for success on a risky-choice task. Possession of this polymorphism induced disadvantageous choice behavior in the Iowa Gambling Task (IGT) due either to lack of persistence or slower acquisition of successful decision-making [197,198]. Failure to learn from faulty decision-making resulting in punishment presents a different aspect of impulse-control impairment; possibly, 5HTTLPR variations modulate sensitivity to punishments, since LL homozygous individuals were less sensitive to punishment-related information [199,200].

Impulsive behavior, broadly “action without foresight” (cf. [176]), may be linked strongly to aggressive acts (impulsive aggression) and variations in serotonin neurotransmission with or without ADHD diagnosis [201–205]. Failure of executive inhibitory functioning is linked to the emotional lability and dysfunctional motor control expressed in impulsive aggressiveness [206–209], often displayed in maladaptive responding and inappropriate actions of ADHD individuals [210–212]. For example, maladaptive and impaired, impulsive decision-making linked to emotional dysregulation, the real/potential endophenotypes, and modulated by serotonergic genotypes associated with suicidal behavior, have presented relevant markers for identification of patients with vulnerability [213]. ADHD children have displayed greater impairment in controlled than automatic response processing and inhibition [214]; these disorder states have been shown to be related to ADHD [215–217] and notably serotonergic functioning in ADHD [218–222]. Using a family-based association test (FBAT-PC), Oades et al. [223] found a genetic influence on both serotonergic and dopaminergic involvement in impulsiveness by ADHD children: Trends for separate and overlapping influences on impulsive-aggressiveness (TPH, HTR1E) and cognitive-impulsiveness (SERT/SLC6A4 variant), with phenylethanolamine N-methyltransferase association, were obtained. Salo et al. [224] studied the interaction between polymorphisms of COMT and serotonin receptor 2A genes in a subsample of 1214 healthy Finnish adult volunteers. They demonstrated an interaction between COMT Val158Met and HTR2A T102C polymorphisms associated with impulsiveness. T/T carriers of HTR2A T102C polymorphism, that possessed also the Met/Met genotype of COMT Val158Met SNP, scored significantly higher on impulsiveness than the Val allele carriers thereby further

emphasising the interactions between dopaminergic and serotonergic genes underlying impulsiveness.

Studies manipulating serotonergic neurotransmission through, e.g., tryptophan availability alterations, further demonstrate a role in decision-making and impulsive behavior [225–228], with tryptophan supplements improving decision-making [229]. Using a rapid, event-related go/no-go task, Rubia et al. [230] found that acute tryptophan depletion significantly reduced right orbito-inferior prefrontal activation during the no-go condition, and increased activation in superior and medial temporal cortices, thereby indicating serotonergic modulation of right inferior prefrontal cortex during inhibitory motor control. Jollant et al. [231] observed that genetic variations in the tryptophan hydroxylase 1 and 2, TPH1, and TPH2 genes and MAOA gene were associated with worse IGT performance in suicide attempters. Variations in the TPH2 gene have been implicated repeatedly in suicidal behavior and neuropsychiatric disorders [232–235]. Juhasz et al. [236] genotyped seven haplotype tagging SNPs in the TPH2 gene, as well as previously reported functional polymorphisms from the other genes (rs1800532, 5HTTLPR, and rs6295), and assessed risk-taking behavior using the IGT. They found that carriers of the more prevalent haplotype evidenced less risk-taking on the tasks applied. In order to examine mechanisms by which serotonergic neurotransmission affects impulsivity, Walderhaug et al. [237] studied the triallelic system of the serotonin transporter gene linked polymorphic region (5-HTTLPR) and acute manipulation of serotonin in 52 healthy participants (38 men and 14 women) receiving acute tryptophan depletion or placebo in a randomized, double-blind, parallel group experiment, using a test of response control. They obtained a dose-dependent effect for the short (S') allele of the 5-HTTLPR upon subjects' impulsive responding, whereby individuals with the S'/S' genotype were more impulsive than individuals with the L/S' genotype, who in turn were more impulsive than the L/L genotype. Acute tryptophan depletion increased impulsiveness in male participants but decreased impulsiveness in female participants.

To investigate epigenetic influences on serotonergic genes, Kinally et al. [238] developed an experimental Rhesus macaque model of early life stress to test whether or not epigenetic regulation of the 5-HTT may contribute to G × E interactions that influence behavior and emotion. They studied 87 infant monkeys (3–4 months of age) that were either mother reared in large social groups (n=70) or nursery reared (n=17), and during maternal/social separation, the infants' blood was sampled and behavioral stress reactivity recorded, with PBMC DNA and RNA samples were used to determine rh5-HTTLPR genotype. As observed with human subjects, the carriers of the low-expressing rh5-HTTLPR alleles exhibited higher mean 5-HTT CpG methylation, which was associated with lower PBMC 5-HTT expression. Higher 5-HTT CpG methylation, but not rh5-HTTLPR genotype, exacerbated the effects of early life stress on behavioral stress reactivity in infants. As a landmark in epigenetics, Caspi et al. [239] showed the interaction of stressful environment and genetic variation of 5-HTTLPR on suicidality through which individuals with one or two copies of the short (s) allele were more vulnerable to adversity than individuals homozygous for the long (l) allele. In this context, Jacob et al. [240] studied the interactions of serotonergic candidate genes, including 5-HTT, HTR1A and TPH2, with burden of life events in 183 adult patients presenting personality disorders and 123 presenting adult ADHD. They observed that only the G allele of HTR1A rs6295 increased the risk of emotional-dramatic cluster B personality disorders, and decreased risk of anxious-fearful cluster C. There was nominal evidence of 5-HTTLPR and TPH2 SNP rs4570625 on personality disorder occurrence.

Noradrenaline-Regulating Genes in ADHD

There are several converging lines of evidence implicating dysregulations in noradrenergic functions in the pathophysiology of ADHD [241], and alterations in noradrenaline-influencing genes [242–244]. Nevertheless, as in the cases of both dopamine and serotonin, a number of studies have failed to obtain any association [174,245,246]. Barr et al. [247] tested the gene for the noradrenaline transporter (NET1) as a putative susceptibility factor for ADHD by applying three polymorphisms located in exon 9, intron 9, and intron 13. They examined the inheritance of these polymorphisms in a sample of 122 families with a total of 155 children with ADHD identified through an ADHD proband. They investigated this gene by screening the probands for five known amino acid variants to determine whether or not they contributed to the ADHD phenotype but observed only one (Thr99Ile) in the sample. They indicated that since the frequency of this variant (1.8%) was similar to that previously reported in a control sample (2.2%), it was unlikely that this variant is related to the ADHD phenotype; thus, their results failed to support the NET1 gene as a major genetic susceptibility factor in ADHD. On the other hand, Roman et al. [248] tested for association between the dopamine- β -hydroxylase (DBH) gene and ADHD in a sample of 88 Brazilian nuclear families. The haplotype relative risk (HRR) analysis of the DBH TaqI restriction site polymorphism had shown a preferential transmission of the TaqI A2 allele in their whole ADHD sample. They found that the significant effect of the A2 allele was stronger when only families with no ADHD parental diagnosis were considered, suggesting the contribution of this gene to ADHD susceptibility.

Using preparations of prepared gene expression profiles of *in vitro* differentiating wild type and norepinephrine transporter-deficient (NETKO) mouse neural crest cells with long serial analysis of gene expression (LongSAGE), Hu et al. [249] showed loss of NET function during embryonic development in the mouse deregulates signalling pathways that are critically involved in neural crest formation and noradrenergic cell differentiation. Kollins et al. [250] applied haplotype-tagging SNP analyses in order to identify molecular genetic substrates of quantitative phenotypes derived from performance on a Continuous Performance Task (CPT) in 364 individuals sampled from 152 families, with probands, their affected and unaffected siblings, and parents. The CPT measures sustained and selective attention and impulsivity by requiring individuals to press (or not press) certain keys depending on the stimulus that flashes on a computer screen. The test usually lasts between 14 and 20 minutes and is designed purposely to be repetitive and monotonous. Good performance requires individuals to sustain their attention to a selectively boring task and to refrain from impulsive responding. Errors of omission, i.e., failure to press the designated key in response to the target stimulus flashing, and errors of commission, i.e., key-pressing responses to a non-target stimulus, together with several other variables, e.g., reaction time and reaction time variability, are computed; individuals' scores may be compared then to typical performance by individuals with the same age, gender, etc. In the study by Kollins et al. [250], significant associations were identified between CPT commission errors and SNPs in the DRD2 gene (rs2075654, rs1079596), and between reaction time variability and a SNP in the NET gene (rs3785155). Errors of commission occurred when subjects answered a question incorrectly; a pattern of heightened emotional reactivity and commission errors is typical for individuals with elevated dissociation scores [251]. On the other hand, Hess et al. [252] carried out association tests with DBH genotypes on four independent samples: healthy volunteers (n=387), patients presenting affective disorders (n=182), adult ADHD patients (n=407), and patients presenting personality disorders (n=637). Their results suggested a dimensional rather than categorical effect of genetic variance in DBH activity, possibly due to the underlying association of the TT genotype at DBH-1021 with impulsive personality traits. Dissociative symptoms have been found to be increased in ADHD individuals [253–256]. Joung et al. [257] performed the genetic association study for a

functional -3081(A/T) polymorphism, located in the promoter region of SLC6A2, the norepinephrine transporter gene and a possible candidate gene for ADHD, in a Korean population of 103 male patients with ADHD and 103 normal male controls. Their findings provided further evidence of association between ADHD and -3081(A/T) polymorphism of SLC6A2 (see above).

Neurotrophic Factor-Regulating Genes in ADHD

Neurotrophic factors, participating in the neurodevelopment, survival, and functional maintenance of brain systems, are involved in neuroplasticity alterations underlying brain disorders and are implicated in the genetic predisposition to ADHD [39,258,259]. The BDNF gene, located at 11p13-14, has several SNPs, most common is rs6265, as evidenced by the observation of elevated BDNF serum levels in Met allele carriers [260]. Despite ubiquitous inconsistent findings (e.g., [261,262]), several investigations support the BDNF association involvement in ADHD [263-266] (but see also [267]). Conner et al. [210] found that among NTF3, NTRK2 (TrkB), NTRK3 (TrkC), BDNF, and p75(NTR), none of the SNPs showed significant association with ADHD symptoms, except for one polymorphism within the exon of NTF3 (rs6332) that showed a trend toward an association between the A-allele and increased scores using both the retrospective childhood analysis Wender-Utah Rating Scale and the adult ADHD assessment Wender-Reimherr interview. In order to attempt a consolidation of inconsistencies among case-control and family-based associations pertaining to p.Val66Met involvement in ADHD, Sanchez-Mora et al. [268] performed a meta-analysis of published data and described unpublished case-control data from four different centres in Germany, the Netherlands, Norway, and Spain, with a total of 1445 adult ADHD patients and 2247 gender-matched healthy controls. They obtained no association between the p.Val66Met polymorphism and ADHD in the pooled sample; nor did they observe any overall gene effect for the disorder after controlling for gender effects and comorbidity with mood disorders.

Aureli et al. [269] genotyped paediatric patients presenting ADHD and/or intellectual disability for the Val66Met and 270 C/T polymorphisms in BDNF. The notion of intellectual disability encompasses various cognitive deficits, including mental retardation, deficits too mild to properly qualify as mental retardation, various specific conditions (e.g., learning disability), and problems acquired later in life through acquired brain injuries or neurodegenerative disorders, including dementias; these may appear at any age. The diagnosis of ADHD and intellectual disability was confirmed by the clinicians in accordance with DSM-IV criteria. They observed that the G/A genotype of the Val66Met SNP was associated with both ADHD and intellectual disability, and further that the G allele was significantly associated with ADHD. The C/C genotype of the C270T SNP was significantly overrepresented in ADHD and intellectual disability groups compared with the controls. These findings suggested that both BDNF polymorphisms could play a role in the etiology of ADHD [269]. From another perspective, van Beijsterveldt et al. [270] have developed a parental-assessment report at ages 3, 7, 10, and 12 years over more than 16,000 twin pairs that 1148 genotyped children presenting attention disorder, a cornerstone of ADHD. They developed a longitudinal framework to test genetic association effects with 26 SNPs of genes encoding for several putative contributors to ADHD, including HTR2A, COMT, TPH2, and BDNF. They found that the broad heritability for the AP latent factor was 82%, and the latent factor explained around 55% of the total phenotypic variance, yet none of the SNPs showed a significant association with attentional problems.

The most commonly applied instrument for ADHD diagnosis is the CPT. As noted earlier, in a typical CPT set-up, an individual sits in front of a computer terminal and is required to press (or not press) certain keys depending on the stimulus that flashes on the screen. Good

performance requires individuals to sustain their attention to a selectively boring task and to refrain from impulsive responding. Performance measures of individuals with ADHD are compared to performance by appropriate control individuals. Thus, the CPT in conjunction with genotyping, provide important tools for defining ADHD gene involvement. For example, Dresler et al. [271] applied the CPT to examine the influence of the common 9- and 10-repeat alleles of SLC6A3 on prefrontal brain functioning and cognitive response control in a large sample of adult ADHD patients (n=161) and healthy controls (n=109). Within the group of ADHD patients, nine-repeat allele carriers showed significantly reduced cognitive response control, whereas no influence of SLC6A3 genotype was observed in the control group. In contrast to previous association studies of children, the nine-repeat-not the 10-repeat-allele was associated with functional impairments in their sample of adult ADHD patients. In this respect, Cho et al. [272] evaluated the effects of the adrenergic α -2A receptor (ADRA2A) and BDNF gene-gene interaction on CPT performance, measuring individuals' sustained and selective attention, and impulsiveness, in a Korean population with ADHD. In total, 122 ADHD participants (8.6±2.3 years, 104 boys and 18 girls) completed the CPT. They genotyped the DraI polymorphism of ADRA2A (rs583668) and rs11030101 polymorphism of BDNF, and obtained significant interaction effect of the ADRA2A rs553668 and BDNF rs11030101 for response time variability of the CPT. This study thus offered preliminary evidence for the effect of the BDNF and ADRA2A gene-gene interaction on performance on the CPT in ADHD.

Epigenetic Regulation of Intervention

Therapeutic intervention in ADHD is complicated by marked comorbidity within symptoms domains that have linked the disorder with academic underachievement, substance abuse and dependence, psychosocial problems and social maladjustment, unemployment in adulthood, as well as executive dysfunctioning and borderline personality disorder [273–275]. In this vein, several twin studies have reported that the covariation ADHD and combined ODD/CD symptoms and between ADHD and CD symptoms was explained largely on the basis of common genetic risk factors [73,276–279], but not always (e.g., [280]). Nevertheless, although inattentive and hyperactive-impulsive symptoms were likely influenced by common as well as specific genetic risk factors, certain family environmental risk factors have been discussed for this area of comorbidity [281]. Tuvblad et al. [282] examined the genetic and environmental correlations among ADHD, ODD, and CD in 1219 twins (aged 9–10 years) that included 605 families from the larger Los Angeles community. Externalizing behavior, i.e., aggression, delinquency, and hyperactivity [283], was reported to explain the covariance among those disorder symptoms. The authors have indicated that genetic influences explained more than half of the variance in the externalizing factor but that there were unique genetic and environmental influences in each set of symptoms. Vanyukov et al. [284] found that the strength of association between ADHD, CD, ODD, and parenting index depended on the MAOA genotype (whether low-activity or high activity), and parental gender (see above). MAOA polymorphism linkage with substance abuse disorders was detected when parenting was controlled for.

Genetic linkage studies of ADHD pharmacological intervention have demonstrated that associations have fitted the *drug response phenotype* rather than the disorder diagnosis (cf. [90,285]). Methylphenidate binds to the dopamine transporter and blocks its activity [286]; the behavior response to the compound may be moderated by genetic variants affecting aspects of dopamine transporter structure-function parameters. Joobar et al. [120] showed that the 3'-UTR VNTR polymorphism in the dopamine transporter gene modulated the behavior response to methylphenidate (see also [287–290]). Thakur et al. [291] assessed ADHD patients, aged 6 to 12 years (n=157) with regard to their behavior response to methylphenidate and genotyped them for the triallelic 5-HTTLPR polymorphism in the

SLC6A4 gene. They obtained a significant Gene \times Treatment interaction effect for CGI-parents (assessment) but not CGI-teachers. Children homozygous for the lower expressing alleles ($s+I_G=s'$) responded well to placebo without additional improvement by the compound, compared to children carrying a higher expressing allele (I_A). Kereszturi et al. [292] reported a significant role of the high activity Val-allele of COMT Val158Met polymorphism in their ADHD sample. By applying a categorical analysis of 90 responders vs. 32 non-responders, they found an association between the Val-allele or Val/Val genotype and good methylphenidate response. Analyzing symptom severity as a continuous trait, a significant interaction of COMT genotype and methylphenidate was found on the Hyperactivity-Impulsivity scale. Symptom severity scores of all three genotype groups decreased following methylphenidate administration but the Val/Val homozygote children expressed significantly less severe symptoms than those with Met/Met genotype after treatment ($p=0.015$). In a randomized, within-subject, double-blind design in which 58 ADHD children (ages 6–12 years) received placebo, 0.15, 0.3, or 0.6 mg/kg of MPH three times daily over nine weeks, Leddy et al. [293] measured percent lunch consumed as a function of dopamine-related genotypes and MPH dose. They obtained a significant dose-response reduction in eating across all genotypes measured, as well as a significant interaction of dose with DAT SLC6A3 and DRD2 genotypes. Additionally, Cheon et al. [294] have shown existence of an association between the 4-repeat allele at DRD4 and good response to MPH in Korean ADHD children. Palmason et al. [295] showed that the Met allele of the COMT Val(158)Met SNP was associated with increased ADHD symptom severity, without co-morbid CD. ADHD symptom severity and early adverse familial environment were positive predictors of lifetime, thereby emphasizing the need for early intervention. Finally, high levels of comorbidity of ADHD with other disorders strongly suggests complex epistatic or pleiotropic effects acting in common with the environmental influences [296,297].

In studies of ADHD, dysfunctional and dysregulated neurotransmitter systems, e.g., dopamine, have been linked to impairments of sustained (continuous performance) attention, inhibitory control, and working memory [298]. Cognitive and neurobehavioral studies that focus on particular tasks, reaction time, and verbal working memory, with concomitant neuroimaging provide exhaustive criteria for ADHD endophenotypes and a bridge between observed traits and genetic vulnerability. Bidwell et al. [299] collected DNA in 202 families consisting of at least one ADHD proband and at least one parent or sibling. They found that VNTR polymorphisms of the DRD4 and DAT1 genes were associated significantly with the ADHD phenotype. The association with DRD4 was driven by both inattentive and hyperactive symptoms, whereas the association with DAT1 was driven primarily by inattentive symptoms.

Conclusions

The epigenetic aspect to ADHD involves a multiplicity of complex genotyped entities, environmental realities, and endophenotypes that interact to express the gene structural material, the symptom-profiles inherent to disorder pathophysiology, and the eventual responses to the therapeutic intervention, namely methylphenidate. There exists much variability and conflicting evidence for the existence, or not, of genetic associations between disorder diagnosis and genes regulating the structure and function of dopamine, serotonin, and noradrenaline, and the neurotrophic factor, BDNF. Nevertheless, the results pertaining to associations between symptoms-profiles, synonymously endophenotypes, such as lack of attention, overactivity, lack of impulse control, or overeating, appear surprisingly reassuring. The genomewide association studies carried out on ADHD population samples have failed to identify replicable associations that explain plausibly the heritable variation, but twin studies have provided sufficient instruments in the development of endophenotypes, defined

as alternative, more highly heritable traits that act at earlier stages of the pathway from genes to behavior.

Acknowledgments

The writing of this paper was supported in part by the US Department of Health and Human Services, NIAAA (R01 AA 07112, K05 AA 00219), and by the Medical Research Service of the US Department of Veterans Affairs.

References

1. Plomin R, McGuffin P. Psychopathology in the postgenomic era. *Annu Rev Psychol.* 2003; 54:205–228. [PubMed: 12172001]
2. Caspi A, Hariri AR, Holmes A, Uher R, Moffitt TE. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. *Am J Psychiatry.* 2010; 167:509–527. [PubMed: 20231323]
3. Caspi A, Moffitt TE. Gene-environment interactions in psychiatry: joining forces with neuroscience. *Nat Rev Neurosci.* 2006; 7:583–590. [PubMed: 16791147]
4. Turnpenny PD, Ellard S. *Emery's Elements of Medical Genetics.* Churchill Living Stone (13th Edition). 2007
5. Kovas Y, Plomin R. Generalist genes: implications for the cognitive sciences. *Trends Cogn Sci.* 2006; 10:198–203. [PubMed: 16580870]
6. Wong CC, Schumann G. Review. Genetics of addictions: strategies for addressing heterogeneity and polygenicity of substance use disorders. *Philos Trans R Soc Lond B Biol Sci.* 2008; 363:3213–3222. [PubMed: 18640915]
7. Morrison JR, Stewart MA. Bilateral inheritance as evidence for polygenicity in the hyperactive child syndrome. *J Nerv Ment Dis.* 1974; 158:226–228. [PubMed: 4815672]
8. Rutter, M. *Genes and Behavior: Nature-Nurture Interplay Explained.* London: Blackwell; 2006.
9. Pennington BF, McGrath LM, Rosenberg J, Barnard H, Smith SD, et al. Gene X environment interactions in reading disability and attention-deficit/hyperactivity disorder. *Dev Psychol.* 2009; 45:77–89. [PubMed: 19209992]
10. Rumbaugh G, Miller CA. Epigenetic changes in the brain: measuring global histone modifications. *Methods Mol Biol.* 2011; 670:263–274. [PubMed: 20967596]
11. Graff J, Mansuy IM. Epigenetic dysregulation in cognitive disorders. *Eur J Neurosci.* 2009; 30:1–8. [PubMed: 19508697]
12. Mehler MF, Purpura DP. Autism, fever, epigenetics and the locus coeruleus. *Brain Res Rev.* 2009; 59:388–392. [PubMed: 19059284]
13. Miller CA, Campbell SL, Sweatt JD. DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. *Neurobiol Learn Mem.* 2008; 89:599–603. [PubMed: 17881251]
14. Steinhausen HC. The heterogeneity of causes and courses of attention-deficit/hyperactivity disorder. *Acta Psychiatr Scand.* 2009; 120:392–399. [PubMed: 19807721]
15. Nigg J, Nikolas M, Burt SA. Measured gene-by-environment interaction in relation to attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry.* 2010; 49:863–873. [PubMed: 20732623]
16. Wong CC, Caspi A, Williams B, Craig IW, Houts R, et al. A longitudinal study of epigenetic variation in twins. *Epigenetics.* 2010; 5:516–526. [PubMed: 20505345]
17. Doyle AE, Ferreira MA, Sklar PB, Lasky-Su J, Petty C, et al. Multivariate genomewide linkage scan of neurocognitive traits and ADHD symptoms: suggestive linkage to 3q13. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B:1399–1411. [PubMed: 18973233]
18. Gluckman PD, Hanson MA. Developmental and epigenetic pathways to obesity: an evolutionary-developmental perspective. *Int J Obes (Lond).* 2008; 32 Suppl 7:S62–S71. [PubMed: 19136993]
19. Gluckman PD, Hanson MA, Buklijas T, Low FM, Beedle AS. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. *Nat Rev Endocrinol.* 2009; 5:401–408. [PubMed: 19488075]

20. Holliday R. DNA methylation and epigenotypes. *Biochemistry (Mosc)*. 2005; 70:500–504. [PubMed: 15948704]
21. Holliday R. Epigenetics: a historical overview. *Epigenetics*. 2006; 1:76–80. [PubMed: 17998809]
22. Henikoff S, Matzke MA. Exploring and explaining epigenetic effects. *Trends Genet*. 1997; 13:293–295. [PubMed: 9260513]
23. House SH. Nurturing the brain nutritionally and emotionally from before conception to late adolescence. *Nutr Health*. 2007; 19:143–161. [PubMed: 18309773]
24. Goos LM, Ragsdale G. Genomic imprinting and human psychology: cognition, behavior and pathology. *Adv Exp Med Biol*. 2008; 626:71–88. [PubMed: 18372792]
25. Ribases M, Bosch R, Hervas A, Ramos-Quiroga JA, Sanchez-Mora C, et al. Case-control study of six genes asymmetrically expressed in the two cerebral hemispheres: association of BAIAP2 with attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2009; 66:926–934. [PubMed: 19733838]
26. Franke B, Vasquez AA, Johansson S, Hoogman M, Romanos J, et al. Multicenter analysis of the SLC6A3/DAT1 VNTR haplotype in persistent ADHD suggests differential involvement of the gene in childhood and persistent ADHD. *Neuropsychopharmacology*. 2009; 35:656–664. [PubMed: 19890261]
27. Johansson S, Halmoy A, Mavroconstanti T, Jacobsen KK, Landaas ET, et al. Common variants in the TPH1 and TPH2 regions are not associated with persistent ADHD in a combined sample of 1,636 adult cases and 1,923 controls from four European populations. *Am J Med Genet B Neuropsychiatr Genet*. 2010; 153B:1008–1015. [PubMed: 20213726]
28. Ernst M, Moolchan ET, Robinson ML. Behavioral and neural consequences of prenatal exposure to nicotine. *J Am Acad Child Adolesc Psychiatry*. 2001; 40:630–641. [PubMed: 11392340]
29. Huizink AC, Mulder EJ. Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring. *Neurosci Biobehav Rev*. 2006; 30:24–41. [PubMed: 16095697]
30. Jacobson JL, Jacobson SW. Prenatal exposure to polychlorinated biphenyls and attention at school age. *J Pediatr*. 2003; 143:780–788. [PubMed: 14657828]
31. Meschke LL, Holl JA, Messelt S. Assessing the risk of fetal alcohol syndrome: understanding substance use among pregnant women. *Neurotoxicol Teratol*. 2003; 25:667–674. [PubMed: 14624965]
32. O'Connor TG, Heron J, Golding J, Beveridge M, Glover V. Maternal antenatal anxiety and children's behavioural/emotional problems at 4 years. Report from the Avon Longitudinal Study of Parents and Children. *Br J Psychiatry*. 2002; 180:502–508. [PubMed: 12042228]
33. Holene E, Nafstad I, Skaare JU, Sagvolden T. Behavioural hyperactivity in rats following postnatal exposure to sub-toxic doses of polychlorinated biphenyl congeners 153 and 126. *Behav Brain Res*. 1998; 94:213–224. [PubMed: 9708851]
34. Nigg JT, Breslau N. Prenatal smoking exposure, low birth weight, and disruptive behavior disorders. *J Am Acad Child Adolesc Psychiatry*. 2007; 46:362–369. [PubMed: 17314722]
35. Ribas-Fito N, Torrent M, Carrizo D, Julvez J, Grimalt JO, et al. Exposure to hexachlorobenzene during pregnancy and children's social behavior at 4 years of age. *Environ Health Perspect*. 2007; 115:447–450. [PubMed: 17431497]
36. Neugebauer R, Hoek HW, Susser E. Prenatal exposure to wartime famine and development of antisocial personality disorder in early adulthood. *JAMA*. 1999; 282:455–462. [PubMed: 10442661]
37. Teicher MH, Andersen SL, Polcari A, Anderson CM, Navalta CP, et al. The neurobiological consequences of early stress and childhood maltreatment. *Neurosci Biobehav Rev*. 2003; 27:33–44. [PubMed: 12732221]
38. Archer T, Kostrzewa RM, Beninger RJ, Palomo T. Staging perspectives in neurodevelopmental aspects of neuropsychiatry: agents, phases and ages at expression. *Neurotox Res*. 2010; 18:287–305. [PubMed: 20237881]
39. Archer T. Effects of Exogenous Agents on Brain Development: Stress, Abuse and Therapeutic Compounds. *CNS Neurosci Ther*. 2010

40. Talge NM, Neal C, Glover V. Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? *J Child Psychol Psychiatry*. 2007; 48:245–261. [PubMed: 17355398]
41. Weinstock M. Alterations induced by gestational stress in brain morphology and behaviour of the offspring. *Prog Neurobiol*. 2001; 65:427–451. [PubMed: 11689280]
42. Phillips DI. Programming of the stress response: a fundamental mechanism underlying the long-term effects of the fetal environment? *J Intern Med*. 2007; 261:453–460. [PubMed: 17444884]
43. Phillips DI, Jones A, Goulden PA. Birth weight, stress, and the metabolic syndrome in adult life. *Ann N Y Acad Sci*. 2006; 1083:28–36. [PubMed: 17148731]
44. Liang G, Chen M, Pan XL, Zheng J, Wang H. Ethanol-induced inhibition of fetal hypothalamic-pituitary-adrenal axis due to prenatal overexposure to maternal glucocorticoid in mice. *Exp Toxicol Pathol*. 2010
45. Vieau D, Sebaai N, Leonhardt M, Dutriez-Casteloot I, Molendi-Coste O, et al. HPA axis programming by maternal undernutrition in the male rat offspring. *Psychoneuroendocrinology*. 2007; 32 Suppl 1:S16–S20. [PubMed: 17644270]
46. Ke X, Schober ME, McKnight RA, O’Grady S, Caprau D, et al. Intrauterine growth retardation affects expression and epigenetic characteristics of the rat hippocampal glucocorticoid receptor gene. *Physiol Genomics*. 2010; 42:177–189. [PubMed: 20388836]
47. Weaver IC. Epigenetic programming by maternal behavior and pharmacological intervention. Nature versus nurture: let’s call the whole thing off. *Epigenetics*. 2007; 2:22–28. [PubMed: 17965624]
48. Dolinoy DC, Weidman JR, Jirtle RL. Epigenetic gene regulation: linking early developmental environment to adult disease. *Reprod Toxicol*. 2007; 23:297–307. [PubMed: 17046196]
49. Jaffee SR, Price TS. Gene-environment correlations: a review of the evidence and implications for prevention of mental illness. *Mol Psychiatry*. 2007; 12:432–442. [PubMed: 17453060]
50. Lillycrop KA, Slater-Jefferies JL, Hanson MA, Godfrey KM, Jackson AA, et al. Induction of altered epigenetic regulation of the hepatic glucocorticoid receptor in the offspring of rats fed a protein-restricted diet during pregnancy suggests that reduced DNA methyltransferase-1 expression is involved in impaired DNA methylation and changes in histone modifications. *Br J Nutr*. 2007; 97:1064–1073. [PubMed: 17433129]
51. Linnert KM, Dalsgaard S, Obel C, Wisborg K, Henriksen TB, et al. Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. *Am J Psychiatry*. 2003; 160:1028–1040. [PubMed: 12777257]
52. Linnert KM, Wisborg K, Obel C, Secher NJ, Thomsen PH, et al. Smoking during pregnancy and the risk for hyperkinetic disorder in offspring. *Pediatrics*. 2005; 116:462–467. [PubMed: 16061604]
53. Van den Bergh BR, Mulder EJ, Mennes M, Glover V. Antenatal maternal anxiety and stress and the neurobehavioural development of the fetus and child: links and possible mechanisms. A review. *Neurosci Biobehav Rev*. 2005; 29:237–258. [PubMed: 15811496]
54. Finer S, Holland ML, Nanty L, Rakyan VK. The hunt for the epiallele. *Environ Mol Mutagen*. 2010; 52:1–11. [PubMed: 20839222]
55. Burdge GC, Lillycrop KA. Nutrition, epigenetics, and developmental plasticity: implications for understanding human disease. *Annu Rev Nutr*. 2010; 30:315–339. [PubMed: 20415585]
56. Jabbari K, Bernardi G. Cytosine methylation and CpG, TpG (CpA) and TpA frequencies. *Gene*. 2004; 333:143–149. [PubMed: 15177689]
57. Attig L, Gabory A, Junien C. Early nutrition and epigenetic programming: chasing shadows. *Curr Opin Clin Nutr Metab Care*. 2010; 13:284–293. [PubMed: 20375884]
58. Attig L, Gabory A, Junien C. Nutritional developmental epigenomics: immediate and long-lasting effects. *Proc Nutr Soc*. 2010; 69:221–231. [PubMed: 20202279]
59. Morgan DK, Whitelaw E. The role of epigenetics in mediating environmental effects on phenotype. *Nestle Nutr Workshop Ser Pediatr Program*. 2009; 63:109–117. discussion 117–109, 259–168.
60. Rakyan VK, Blewitt ME, Druker R, Preis JJ, Whitelaw E. Metastable epialleles in mammals. *Trends Genet*. 2002; 18:348–351. [PubMed: 12127774]

61. Dolinoy DC, Weinhouse C, Jones T, Rozek LS, Jirtle RL. Variable histone modifications at the A(vy) metastable epiallele. *Epigenetics*. 2010; 5:637–644. [PubMed: 20671424]
62. Bernal AJ, Jirtle RL. Epigenomic disruption: the effects of early developmental exposures. *Birth Defects Res A Clin Mol Teratol*. 2010; 88:938–944. [PubMed: 20568270]
63. Bell CG, Finer S, Lindgren CM, Wilson GA, Rakyan VK, et al. Integrated genetic and epigenetic analysis identifies haplotype-specific methylation in the FTO type 2 diabetes and obesity susceptibility locus. *PLoS One*. 2010; 5:e14040. [PubMed: 21124985]
64. Biederman J, Milberger S, Faraone SV, Kiely K, Guite J, et al. Impact of adversity on functioning and comorbidity in children with attention-deficit hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 1995; 34:1495–1503. [PubMed: 8543518]
65. Biederman J, Milberger S, Faraone SV, Kiely K, Guite J, et al. Family-environment risk factors for attention-deficit hyperactivity disorder. A test of Rutter's indicators of adversity. *Arch Gen Psychiatry*. 1995; 52:464–470. [PubMed: 7771916]
66. Hausknecht KA, Acheson A, Farrar AM, Kieres AK, Shen RY, et al. Prenatal alcohol exposure causes attention deficits in male rats. *Behav Neurosci*. 2005; 119:302–310. [PubMed: 15727534]
67. Kahn RS, Khoury J, Nichols WC, Lanphear BP. Role of dopamine transporter genotype and maternal prenatal smoking in childhood hyperactive-impulsive, inattentive, and oppositional behaviors. *J Pediatr*. 2003; 143:104–110. [PubMed: 12915833]
68. Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children --- United States, 2003 and 2007. *MMWR Morb Mortal Wkly Rep*. 2010; 59:1439–1443. [PubMed: 21063274]
69. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and meta-regression analysis. *Am J Psychiatry*. 2007; 164:942–948. [PubMed: 17541055]
70. Sanchez EY, Velarde S, Britton GB. Estimated Prevalence of Attention-Deficit/Hyperactivity Disorder in a Sample of Panamanian School-Aged Children. *Child Psychiatry Hum Dev*. 2010; 42:243–255. [PubMed: 21127963]
71. Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. *JAMA*. 2001; 285:60–66. [PubMed: 11150110]
72. Gustafsson P, Kallen K. Perinatal, maternal, and fetal characteristics of children diagnosed with attention-deficit-hyperactivity disorder: results from a population-based study utilizing the Swedish Medical Birth Register. *Dev Med Child Neurol*. 2010; 53:263–268. [PubMed: 20964677]
73. Wallis D, Russell HF, Muenke M. Review: Genetics of attention deficit/hyperactivity disorder. *J Pediatr Psychol*. 2008; 33:1085–1099. [PubMed: 18522996]
74. Blum K, Chen AL, Braverman ER, Comings DE, Chen TJ, et al. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. *Neuropsychiatr Dis Treat*. 2008; 4:893–918. [PubMed: 19183781]
75. Elia J, Devoto M. ADHD genetics: 2007 update. *Curr Psychiatry Rep*. 2007; 9:434–439. [PubMed: 17915085]
76. Forero DA, Arboleda GH, Vasquez R, Arboleda H. Candidate genes involved in neural plasticity and the risk for attention-deficit hyperactivity disorder: a meta-analysis of 8 common variants. *J Psychiatry Neurosci*. 2009; 34:361–366. [PubMed: 19721846]
77. Halperin JM, Healey DM. The influences of environmental enrichment, cognitive enhancement, and physical exercise on brain development: can we alter the developmental trajectory of ADHD? *Neurosci Biobehav Rev*. 2011; 35:621–634. [PubMed: 20691725]
78. Silk TJ, Vance A, Rinehart N, Bradshaw JL, Cunnington R. Structural development of the basal ganglia in attention deficit hyperactivity disorder: a diffusion tensor imaging study. *Psychiatry Res*. 2009; 172:220–225. [PubMed: 19398307]
79. Tiemeier H, Lenroot RK, Greenstein DK, Tran L, Pierson R, et al. Cerebellum development during childhood and adolescence: a longitudinal morphometric MRI study. *Neuroimage*. 2010; 49:63–70. [PubMed: 19683586]

80. Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, et al. Association of attention-deficit disorder and the dopamine transporter gene. *Am J Hum Genet.* 1995; 56:993–998. [PubMed: 7717410]
81. Mill J, Petronis A. Molecular studies of major depressive disorder: the epigenetic perspective. *Mol Psychiatry.* 2007; 12:799–814. [PubMed: 17420765]
82. Petronis A. The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. *Biol Psychiatry.* 2004; 55:965–970. [PubMed: 15121478]
83. Mill J, Petronis A. Pre- and peri-natal environmental risks for attention-deficit hyperactivity disorder (ADHD): the potential role of epigenetic processes in mediating susceptibility. *J Child Psychol Psychiatry.* 2008; 49:1020–1030. [PubMed: 18492038]
84. Accornero VH, Amado AJ, Morrow CE, Xue L, Anthony JC, et al. Impact of prenatal cocaine exposure on attention and response inhibition as assessed by continuous performance tests. *J Dev Behav Pediatr.* 2007; 28:195–205. [PubMed: 17565286]
85. Das M, Bhowmik AD, Bhaduri N, Sarkar K, Ghosh P, et al. Role of gene-gene/gene-environment interaction in the etiology of eastern Indian ADHD probands. *Prog Neuropsychopharmacol Biol Psychiatry.* 2011; 35:577–587. [PubMed: 21216270]
86. Wohl M, Boni C, Asch M, Cortese S, Orejarena S, et al. Lack of association of the dopamine transporter gene in a French ADHD sample. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B:1509–1510. [PubMed: 18214864]
87. Wang Y, Wang Z, Yao K, Tanaka K, Yang Y, et al. Lack of association between the dopamine transporter gene 3' VNTR polymorphism and attention deficit hyperactivity disorder in Chinese Han children: case-control and family-based studies. *Kobe J Med Sci.* 2007; 53:327–333. [PubMed: 18762727]
88. Kopeckova M, Paclt I, Petrasek J, Pacltova D, Malikova M, et al. Some ADHD polymorphisms (in genes DAT1, DRD2, DRD3, DBH, 5-HTT) in case-control study of 100 subjects 6–10 age. *Neuro Endocrinol Lett.* 2008; 29:246–251. [PubMed: 18404133]
89. Henriquez BH, Henriquez HM, Carrasco Ch X, Rothhammer AP, Llop RE, et al. [Combination of DRD4 and DAT1 genotypes is an important risk factor for attention deficit disorder with hyperactivity families living in Santiago, Chile]. *Rev Med Chil.* 2008; 136:719–724. [PubMed: 18769827]
90. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, et al. Molecular genetics of attention-deficit/hyperactivity disorder. *Biol Psychiatry.* 2005; 57:1313–1323. [PubMed: 15950004]
91. Yang B, Chan RCK, Jing J, Li T, Sham P, et al. A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention deficit hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet.* 2007; 144B: 541–550. [PubMed: 17440978]
92. Kebir O, Tabbane K, Sengupta S, Joober R. Candidate genes and neuropsychological phenotypes in children with ADHD: review of association studies. *J Psychiatry Neurosci.* 2009; 34:88–101. [PubMed: 19270759]
93. Brookes K, Xu X, Chen W, Zhou K, Neale B, et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. *Mol Psychiatry.* 2006; 11:934–953. [PubMed: 16894395]
94. Brookes KJ, Neale B, Xu X, Thapar A, Gill M, et al. Differential dopamine receptor D4 allele association with ADHD dependent of proband season of birth. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B:94–99. [PubMed: 17525975]
95. Csuros M, Rogozin IB, Koonin EV. Extremely intron-rich genes in the alveolate ancestors inferred with a flexible maximum-likelihood approach. *Mol Biol Evol.* 2008; 25:903–911. [PubMed: 18296415]
96. Asherson P, Brookes K, Franke B, Chen W, Gill M, et al. Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined-type ADHD. *Am J Psychiatry.* 2007; 164:674–677. [PubMed: 17403983]
97. Gizer I, Ficks C, Waldman I. Candidate gene studies of ADHD: a meta-analytic review. *Hum Genet.* 2009; 126:51–90. [PubMed: 19506906]

98. Glaser RL, Ramsay JP, Morison IM. The imprinted gene and parent-of-origin effect database now includes parental origin of de novo mutations. *Nucleic Acids Res.* 2006; 34:D29–D31. [PubMed: 16381868]
99. Davies W, Isles AR, Wilkinson LS. Imprinted genes and mental dysfunction. *Ann Med.* 2001; 33:428–436. [PubMed: 11585104]
100. Goos LM, Ezzatian P, Schachar R. Parent-of-origin effects in attention-deficit hyperactivity disorder. *Psychiatry Res.* 2007; 149:1–9. [PubMed: 17129611]
101. Lahey BB, Rathouz PJ, Lee SS, Chronis-Tuscano A, Pelham WE, et al. Interactions between early parenting and a polymorphism of the child's dopamine transporter gene in predicting future child conduct disorder symptoms. *J Abnorm Psychol.* 2010; 120:33–45. [PubMed: 21171728]
102. Joobar R, Sengupta S. Parent-of-origin effect and risk for attentiondeficit/ hyperactivity disorder: balancing the evidence against bias and chance findings. *Am J Hum Genet.* 2006; 79:765–766. author reply 766–768. [PubMed: 16960815]
103. Anney RJ, Hawi Z, Sheehan K, Mulligan A, Pinto C, et al. Parent of origin effects in attention/ deficit hyperactivity disorder (ADHD): analysis of data from the international multicenter ADHD genetics (IMAGE) program. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B:1495–1500. [PubMed: 18163388]
104. Hawi Z, Segurado R, Conroy J, Sheehan K, Lowe N, et al. Preferential transmission of paternal alleles at risk genes in attention-deficit/hyperactivity disorder. *Am J Hum Genet.* 2005; 77:958–965. [PubMed: 16380908]
105. Kim JW, Waldman ID, Faraone SV, Biederman J, Doyle AE, et al. Investigation of parent-of-origin effects in ADHD candidate genes. *Am J Med Genet B Neuropsychiatr Genet.* 2007; 144B: 776–780. [PubMed: 17427194]
106. Laurin N, Feng Y, Ickowicz A, Pathare T, Malone M, et al. No preferential transmission of paternal alleles at risk genes in attention-deficit hyperactivity disorder. *Mol Psychiatry.* 2007; 12:226–229. [PubMed: 17325714]
107. Hawi Z, Kent L, Hill M, Anney RJ, Brookes KJ, et al. ADHD and DAT1: further evidence of paternal over-transmission of risk alleles and haplotype. *Am J Med Genet B Neuropsychiatr Genet.* 2010; 153B:97–102. [PubMed: 19388000]
108. Kent L, Green E, Hawi Z, Kirley A, Dudbridge F, et al. Association of the paternally transmitted copy of common Valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor (BDNF) gene with susceptibility to ADHD. *Mol Psychiatry.* 2005; 10:939–943. [PubMed: 15940292]
109. Doyle AE, Faraone SV, Seidman LJ, Willcutt EG, Nigg JT, et al. Are endophenotypes based on measures of executive functions useful for molecular genetic studies of ADHD? *J Child Psychol Psychiatry.* 2005; 46:774–803. [PubMed: 15972070]
110. Doyle AE, Willcutt EG, Seidman LJ, Biederman J, Chouinard VA, et al. Attention-deficit/ hyperactivity disorder endophenotypes. *Biol Psychiatry.* 2005; 57:1324–1335. [PubMed: 15950005]
111. Waldman ID. Statistical approaches to complex phenotypes: evaluating neuropsychological endophenotypes for attention-deficit/hyperactivity disorder. *Biol Psychiatry.* 2005; 57:1347–1356. [PubMed: 15950007]
112. Kuntsi J, Andreou P, Ma J, Borger NA, van der Meere JJ. Testing assumptions for endophenotype studies in ADHD: reliability and validity of tasks in a general population sample. *BMC Psychiatry.* 2005; 5:40. [PubMed: 16262903]
113. Slaats-Willemse D, Swaab-Barneveld H, de Sonnevile L, van der Meulen E, Buitelaar J. Deficient response inhibition as a cognitive endophenotype of ADHD. *J Am Acad Child Adolesc Psychiatry.* 2003; 42:1242–1248. [PubMed: 14560175]
114. Goos LM, Crosbie J, Payne S, Schachar R. Validation and extension of the endophenotype model in ADHD patterns of inheritance in a family study of inhibitory control. *Am J Psychiatry.* 2009; 166:711–717. [PubMed: 19448185]
115. Kistner-Griffin E, Brune CW, Davis LK, Sutcliffe JS, Cox NJ, et al. Parent-of-origin effects of the serotonin transporter gene associated with autism. *Am J Med Genet B Neuropsychiatr Genet.* 2010

116. Wood AC, Neale MC. Twin Studies and Their Implications for Molecular Genetic Studies: Endophenotypes Integrate Quantitative and Molecular Genetics in ADHD Research. *J Am Acad Child Adolesc Psychiatry*. 2010; 49:874–883. [PubMed: 20732624]
117. Hill M, Anney RJ, Gill M, Hawi Z. Functional analysis of intron 8 and 3' UTR variable number of tandem repeats of SLC6A3: differential activity of intron 8 variants. *Pharmacogenomics J*. 2010; 10:442–447. [PubMed: 20029387]
118. Brookes KJ, Xu X, Anney R, Franke B, Zhou K, et al. Association of ADHD with genetic variants in the 5'-region of the dopamine transporter gene: evidence for allelic heterogeneity. *Am J Med Genet B Neuropsychiatr Genet*. 2008; 147B:1519–1523. [PubMed: 18668530]
119. Doyle C, Brookes K, Simpson J, Park J, Scott S, et al. Replication of an association of a promoter polymorphism of the dopamine transporter gene and Attention Deficit Hyperactivity Disorder. *Neurosci Lett*. 2009; 462:179–181. [PubMed: 19576958]
120. Joober R, Grizenko N, Sengupta S, Amor LB, Schmitz N, et al. Dopamine transporter 3'-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylphenidate. *Neuropsychopharmacology*. 2007; 32:1370–1376. [PubMed: 17063150]
121. Laurin N, Ickowicz A, Pathare T, Malone M, Tannock R, et al. Investigation of the G protein subunit Galphalf gene (GNAL) in attention deficit/hyperactivity disorder. *J Psychiatr Res*. 2008; 42:117–124. [PubMed: 17166517]
122. Flouri E, Buchanan A, Tan JP, Griggs J, Attar-Schwartz S. Adverse life events, area socio-economic disadvantage, and adolescent psychopathology: The role of closeness to grandparents in moderating the effect of contextual stress. *Stress*. 2010; 13:402–412. [PubMed: 20666637]
123. Rutter M, Sonuga-Barke EJ. X. Conclusions: overview of findings from the era study, inferences, and research implications. *Monogr Soc Res Child Dev*. 2010; 75:212–229. [PubMed: 20500640]
124. Thabet AM, Al Ghamdi H, Abdulla T, Elhelou MW, Vostanis P. Attention deficit-hyperactivity symptoms among Palestinian children. *East Mediterr Health J*. 2010; 16:505–510. [PubMed: 20799549]
125. McLaughlin KA, Fox NA, Zeanah CH, Sheridan MA, Marshall P, et al. Delayed maturation in brain electrical activity partially explains the association between early environmental deprivation and symptoms of attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2010; 68:329–336. [PubMed: 20497899]
126. Kreppner JM, O'Connor TG, Rutter M. Can inattention/overactivity be an institutional deprivation syndrome? *J Abnorm Child Psychol*. 2001; 29:513–528. [PubMed: 11761285]
127. Kreppner JM, Rutter M, Beckett C, Castle J, Colvert E, et al. Normality and impairment following profound early institutional deprivation: a longitudinal follow-up into early adolescence. *Dev Psychol*. 2007; 43:931–946. [PubMed: 17605526]
128. Racine SE, Culbert KM, Larson CL, Klump KL. The possible influence of impulsivity and dietary restraint on associations between serotonin genes and binge eating. *J Psychiatr Res*. 2009; 43:1278–1286. [PubMed: 19493540]
129. Silva H, Iturra P, Solari A, Villarroel J, Jerez S, et al. Fluoxetine response in impulsive-aggressive behavior and serotonin transporter polymorphism in personality disorder. *Psychiatr Genet*. 2010; 20:25–30. [PubMed: 20010449]
130. Rutter M, Beckett C, Castle J, Colvert E, Kreppner J, et al. Effects of profound early institutional deprivation: an overview of findings from a UK longitudinal study of Romanian adoptees. *Eur J Dev Psychol*. 2007; 4:332–350.
131. Stevens SE, Sonuga-Barke EJ, Kreppner JM, Beckett C, Castle J, et al. Inattention/overactivity following early severe institutional deprivation: presentation and associations in early adolescence. *J Abnorm Child Psychol*. 2008; 36:385–398. [PubMed: 17965931]
132. Laucht M, Skowronek MH, Becker K, Schmidt MH, Esser G, et al. Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample. *Arch Gen Psychiatry*. 2007; 64:585–590. [PubMed: 17485610]
133. Mick E, Faraone SV. Genetics of attention deficit hyperactivity disorder. *Child Adolesc Psychiatr Clin N Am*. 2008; 17:261–284. vii–viii. [PubMed: 18295146]

134. DiMaio S, Grizenko N, Jooper R. Dopamine genes and attention-deficit hyperactivity disorder: a review. *J Psychiatry Neurosci.* 2003; 28:27–38. [PubMed: 12587848]
135. Pliszka SR. The neuropsychopharmacology of attention-deficit/hyperactivity disorder. *Biol Psychiatry.* 2005; 57:1385–1390. [PubMed: 15950012]
136. Stevens SE, Kumsta R, Kreppner JM, Brookes KJ, Rutter M, et al. Dopamine transporter gene polymorphism moderates the effects of severe deprivation on ADHD symptoms: developmental continuities in gene-environment interplay. *Am J Med Genet B Neuropsychiatr Genet.* 2009; 150B:753–761. [PubMed: 19655343]
137. Comings DE, Comings BG, Muhleman D, Dietz G, Shahbahrani B, et al. The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. *JAMA.* 1991; 266:1793–1800. [PubMed: 1832466]
138. Comings DE, Wu S, Chiu C, Ring RH, Gade R, et al. Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes--DRD2, D beta, H, DAT1. *Am J Med Genet.* 1996; 67:264–288. [PubMed: 8725745]
139. Comings DE, Gade-Andavolu R, Gonzalez N, Wu S, Muhleman D, et al. Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder. *Clin Genet.* 2000; 58:31–40. [PubMed: 10945659]
140. Sery O, Drtilkova I, Theiner P, Pitelova R, Staif R, et al. Polymorphism of DRD2 gene and ADHD. *Neuro Endocrinol Lett.* 2006; 27:236–240. [PubMed: 16648784]
141. Paclt I, Drtilkova I, Kopeckova M, Theiner P, Sery O, et al. The association between TaqI A polymorphism of ANKK1 (DRD2) gene and ADHD in the Czech boys aged between 6 and 13 years. *Neuro Endocrinol Lett.* 2010; 31:131–136. [PubMed: 20150882]
142. Esposito-Smythers C, Spirito A, Rizzo C, McGeary JE, Knopik VS. Associations of the DRD2 TaqIA polymorphism with impulsivity and substance use: preliminary results from a clinical sample of adolescents. *Pharmacol Biochem Behav.* 2009; 93:306–312. [PubMed: 19344737]
143. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, et al. Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. *Pharmacogenetics.* 1995; 5:121–141. [PubMed: 7550364]
144. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. *J R Soc Med.* 1996; 89:396–400. [PubMed: 8774539]
145. Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, et al. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. *Theor Biol Med Model.* 2008; 5:24. [PubMed: 19014506]
146. Blum K, Chen AL, Braverman ER, Comings DE, Chen TJ, et al. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. *Neuropsychiatr Dis Treat.* 2008; 4:893–918. [PubMed: 19183781]
147. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. *Prog Brain Res.* 2000; 126:325–341. [PubMed: 11105655]
148. Lahti J, Raikkonen K, Kajantie E, Heinonen K, Pesonen AK, et al. Small body size at birth and behavioural symptoms of ADHD in children aged five to six years. *J Child Psychol Psychiatry.* 2006; 47:1167–1174. [PubMed: 17076756]
149. Strang-Karlsson S, Raikkonen K, Pesonen AK, Kajantie E, Paavonen EJ, et al. Very low birth weight and behavioral symptoms of attention deficit hyperactivity disorder in young adulthood: the Helsinki study of very-low-birth-weight adults. *Am J Psychiatry.* 2008; 165:1345–1353. [PubMed: 18628349]
150. Koot S, van den Bos R, Adriani W, Laviola G. Gender differences in delay-discounting under mild food restriction. *Behav Brain Res.* 2009; 200:134–143. [PubMed: 19373979]
151. Vucetic Z, Totoki K, Schoch H, Whitaker KW, Hill-Smith T, et al. Early life protein restriction alters dopamine circuitry. *Neuroscience.* 2010; 168:359–370. [PubMed: 20394806]
152. Diamond A. Consequences of variations in genes that affect dopamine in prefrontal cortex. *Cereb Cortex.* 2007; 17 Suppl 1:i161–i170. [PubMed: 17725999]

153. Wahlstrom D, White T, Hooper CJ, Vrshek-Schallhorn S, Oetting WS, et al. Variations in the catechol O-methyltransferase polymorphism and prefrontally guided behaviors in adolescents. *Biol Psychiatry*. 2007; 61:626–632. [PubMed: 17014828]
154. Caspi A, Langley K, Milne B, Moffitt TE, O'Donovan M, et al. A replicated molecular genetic basis for subtyping antisocial behavior in children with attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry*. 2008; 65:203–210. [PubMed: 18250258]
155. Nobile M, Rusconi M, Bellina M, Marino C, Giorda R, et al. COMT Val158Met polymorphism and socioeconomic status interact to predict attention deficit/hyperactivity problems in children aged 10–14. *Eur Child Adolesc Psychiatry*. 2010; 19:549–557. [PubMed: 19946720]
156. Nijmeijer JS, Hartman CA, Rommelse NN, Altink ME, Buschgens CJ, et al. Perinatal risk factors interacting with catechol O-methyltransferase and the serotonin transporter gene predict ASD symptoms in children with ADHD. *J Child Psychol Psychiatry*. 2010; 51:1242–1250. [PubMed: 20868372]
157. Ptak C, Petronis A. Epigenetic approaches to psychiatric disorders. *Dialogues Clin Neurosci*. 2010; 12:25–35. [PubMed: 20373664]
158. Ilott NE, Saudino KJ, Asherson P. Genetic influences on attention deficit hyperactivity disorder symptoms from age 2 to 3: a quantitative and molecular genetic investigation. *BMC Psychiatry*. 2010; 10:102. [PubMed: 21122117]
159. Rietveld MJ, Hudziak JJ, Bartels M, van Beijsterveldt CE, Boomsma DI. Heritability of attention problems in children: longitudinal results from a study of twins, age 3 to 12. *J Child Psychol Psychiatry*. 2004; 45:577–588. [PubMed: 15055376]
160. Ha RY, Namkoong K, Kang JI, Kim YT, Kim SJ. Interaction between serotonin transporter promoter and dopamine receptor D4 polymorphisms on decision making. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2009; 33:1217–1222. [PubMed: 19615421]
161. Mick E, Wozniak J, Wilens TE, Biederman J, Faraone SV. Family-based association study of the BDNF, COMT and serotonin transporter genes and DSM-IV bipolar-I disorder in children. *BMC Psychiatry*. 2009; 9:2. [PubMed: 19193231]
162. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. *Pharmacol Biochem Behav*. 2002; 71:533–554. [PubMed: 11888546]
163. Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. *Trends Pharmacol Sci*. 2008; 29:445–453. [PubMed: 19086254]
164. Lowry CA, Hale MW, Evans AK, Heerkens J, Staub DR, et al. Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. *Ann N Y Acad Sci*. 2008; 1148:86–94. [PubMed: 19120094]
165. Murakami H, Matsunaga M, Ohira H. Association of serotonin transporter gene polymorphism and emotion regulation. *Neuroreport*. 2009; 20:414–418. [PubMed: 19223791]
166. Szily E, Bowen J, Unoka Z, Simon L, Keri S. Emotion appraisal is modulated by the genetic polymorphism of the serotonin transporter. *J Neural Transm*. 2008; 115:819–822. [PubMed: 18273536]
167. Adriani W, Leo D, Greco D, Rea M, di Porzio U, et al. Methylphenidate administration to adolescent rats determines plastic changes on reward-related behavior and striatal gene expression. *Neuropsychopharmacology*. 2006; 31:1946–1956. [PubMed: 16319916]
168. Banerjee E, Sinha S, Chatterjee A, Gangopadhyay PK, Singh M, et al. A family-based study of Indian subjects from Kolkata reveals allelic association of the serotonin transporter intron-2 (STin2) polymorphism and attention-deficit-hyperactivity disorder (ADHD). *Am J Med Genet B Neuropsychiatr Genet*. 2006; 141B:361–366. [PubMed: 16583436]
169. Gonda X, Fountoulakis KN, Juhasz G, Rihmer Z, Lazary J, et al. Association of the s allele of the 5-HTTLPR with neuroticism-related traits and temperaments in a psychiatrically healthy population. *Eur Arch Psychiatry Clin Neurosci*. 2009; 259:106–113. [PubMed: 18806915]
170. Gonda X, Fountoulakis KN, Harro J, Pompili M, Akiskal HS, et al. The possible contributory role of the S allele of 5-HTTLPR in the emergence of suicidality. *J Psychopharmacol*. 2010
171. Reuter M, Kirsch P, Hennig J. Inferring candidate genes for attention deficit hyperactivity disorder (ADHD) assessed by the World Health Organization Adult ADHD Self-Report Scale (ASRS). *J Neural Transm*. 2006; 113:929–938. [PubMed: 16362639]

172. Smoller JW, Biederman J, Arbeitman L, Doyle AE, Fagerness J, et al. Association between the 5HT1B receptor gene (HTR1B) and the inattentive subtype of ADHD. *Biol Psychiatry*. 2006; 59:460–467. [PubMed: 16197923]
173. Kim SJ, Badner J, Cheon KA, Kim BN, Yoo HJ, et al. Family-based association study of the serotonin transporter gene polymorphisms in Korean ADHD trios. *Am J Med Genet B Neuropsychiatr Genet*. 2005; 139B:14–18. [PubMed: 16082698]
174. Xu X, Mill J, Chen C-K, Brookes K, Taylor E, et al. Family-based association study of serotonin transporter gene polymorphisms in attention deficit hyperactivity disorder: No evidence for association in UK and Taiwanese samples. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. 2005; 139B:11–13.
175. Wigg KG, Takhar A, Ickowicz A, Tannock R, Kennedy JL, et al. Gene for the serotonin transporter and ADHD: no association with two functional polymorphisms. *Am J Med Genet B Neuropsychiatr Genet*. 2006; 141B:566–570. [PubMed: 16856124]
176. Archer, T. Functional and structural MRI studies on impulsiveness: attention-deficit/hyperactive disorder and borderline personality disorder. In: Bright, P., editor. *Neuroimaging*. 2011. in press
177. Winstanley CA, Eagle DM, Robbins TW. Behavioral models of impulsivity in relation to ADHD: translation between clinical and preclinical studies. *Clin Psychol Rev*. 2006; 26:379–395. [PubMed: 16504359]
178. Clark L, Robbins TW, Ersche KD, Sahakian BJ. Reflection impulsivity in current and former substance users. *Biol Psychiatry*. 2006; 60:515–522. [PubMed: 16448627]
179. Fossati A, Barratt ES, Borroni S, Villa D, Grazioli F, et al. Impulsivity, aggressiveness, and DSM-IV personality disorders. *Psychiatry Res*. 2007; 149:157–167. [PubMed: 17157921]
180. Fountoulakis KN, Iacovides A, Fotiou F, Nimatoudis J, Bascialla F, et al. Neurobiological and psychological correlates of suicidal attempts and thoughts of death in patients with major depression. *Neuropsychobiology*. 2004; 49:42–52. [PubMed: 14730200]
181. Van den Eynde F, Senturk V, Naudts K, Vogels C, Bernagie K, et al. Efficacy of quetiapine for impulsivity and affective symptoms in borderline personality disorder. *J Clin Psychopharmacol*. 2008; 28:147–155. [PubMed: 18344724]
182. Zouk H, Tousignant M, Seguin M, Lesage A, Turecki G. Characterization of impulsivity in suicide completers: clinical, behavioral and psychosocial dimensions. *J Affect Disord*. 2006; 92:195–204. [PubMed: 16545465]
183. Wu S, Comings DE. A common C-1018G polymorphism in the human 5-HT1A receptor gene. *Psychiatr Genet*. 1999; 9:105–106. [PubMed: 10412191]
184. Sawiniec J, Borkowski K, Ginalska G, Lewandowska-Stanek H. Association between 5-hydroxytryptamine 1A receptor gene polymorphism and suicidal behavior. *Przegl Lek*. 2007; 64:208–211. [PubMed: 17724868]
185. Strobel A, Gutknecht L, Rothe C, Reif A, Mossner R, et al. Allelic variation in 5-HT1A receptor expression is associated with anxiety- and depression-related personality traits. *J Neural Transm*. 2003; 110:1445–1453. [PubMed: 14666415]
186. Hettema JM, An SS, van den Oord EJ, Neale MC, Kendler KS, et al. Association study between the serotonin 1A receptor (HTR1A) gene and neuroticism, major depression, and anxiety disorders. *Am J Med Genet B Neuropsychiatr Genet*. 2008; 147B:661–666. [PubMed: 18163385]
187. Koller G, Bondy B, Preuss UW, Zill P, Soyka M. The C(–1019)G 5-HT1A promoter polymorphism and personality traits: no evidence for significant association in alcoholic patients. *Behav Brain Funct*. 2006; 2:7. [PubMed: 16504134]
188. Serretti A, Calati R, Giegling I, Hartmann AM, Moller HJ, et al. Serotonin receptor HTR1A and HTR2C variants and personality traits in suicide attempters and controls. *J Psychiatr Res*. 2009; 43:519–525. [PubMed: 18715570]
189. Benko A, Lazary J, Molnar E, Gonda X, Tothfalusi L, et al. Significant association between the C(–1019)G functional polymorphism of the HTR1A gene and impulsivity. *Am J Med Genet B Neuropsychiatr Genet*. 2009; 153B:592–599. [PubMed: 19725031]
190. Li J, Kang C, Wang Y, Zhou R, Wang B, et al. Contribution of 5-HT2A receptor gene –1438A>G polymorphism to outcome of attention-deficit/hyperactivity disorder in adolescents. *Am J Med Genet B Neuropsychiatr Genet*. 2006; 141B:473–476. [PubMed: 16741915]

191. Li J, Wang Y, Zhou R, Wang B, Zhang H, et al. Association of attention-deficit/hyperactivity disorder with serotonin 4 receptor gene polymorphisms in Han Chinese subjects. *Neurosci Lett*. 2006; 401:6–9. [PubMed: 16563621]
192. Li J, Wang Y, Zhou R, Wang B, Zhang H, et al. No association of attention-deficit/hyperactivity disorder with genes of the serotonergic pathway in Han Chinese subjects. *Neurosci Lett*. 2006; 403:172–175. [PubMed: 16701945]
193. Kuntsi J, Neale BM, Chen W, Faraone SV, Asherson P. The IMAGE project: methodological issues for the molecular genetic analysis of ADHD. *Behav Brain Funct*. 2006; 2:27. [PubMed: 16887023]
194. Ribases M, Ramos-Quiroga JA, Hervas A, Bosch R, Bielsa A, et al. Exploration of 19 serotonergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. *Mol Psychiatry*. 2009; 14:71–85. [PubMed: 17938636]
195. Landaas ET, Johansson S, Jacobsen KK, Ribases M, Bosch R, et al. An international multicenter association study of the serotonin transporter gene in persistent ADHD. *Genes Brain Behav*. 2010; 9:449–458. [PubMed: 20113357]
196. Roiser JP, Rogers RD, Cook LJ, Sahakian BJ. The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls. *Psychopharmacology (Berl)*. 2006; 188:213–227. [PubMed: 16941121]
197. Homberg JR, van den Bos R, den Heijer E, Suer R, Cuppen E. Serotonin transporter dosage modulates long-term decision-making in rat and human. *Neuropharmacology*. 2008; 55:80–84. [PubMed: 18534635]
198. Must A, Juhasz A, Rimanoczy A, Szabo Z, Keri S, et al. Major depressive disorder, serotonin transporter, and personality traits: why patients use suboptimal decision-making strategies? *J Affect Disord*. 2007; 103:273–276. [PubMed: 17382402]
199. Blair KS, Finger E, Marsh AA, Morton J, Mondillo K, et al. The role of 5-HTTLPR in choosing the lesser of two evils, the better of two goods: examining the impact of 5-HTTLPR genotype and tryptophan depletion in object choice. *Psychopharmacology (Berl)*. 2008; 196:29–38. [PubMed: 17940752]
200. Roiser JP, de Martino B, Tan GC, Kumaran D, Seymour B, et al. A genetically mediated bias in decision making driven by failure of amygdala control. *J Neurosci*. 2009; 29:5985–5991. [PubMed: 19420264]
201. Coccaro EF, Kavoussi RJ, Sheline YI, Berman ME, Csernansky JG. Impulsive aggression in personality disorder correlates with platelet 5-HT2A receptor binding. *Neuropsychopharmacology*. 1997; 16:211–216. [PubMed: 9138437]
202. Halperin JM, Sharma V, Siever LJ, Schwartz ST, Matier K, et al. Serotonergic function in aggressive and nonaggressive boys with attention deficit hyperactivity disorder. *Am J Psychiatry*. 1994; 151:243–248. [PubMed: 8296897]
203. Kruesi MJ, Hibbs ED, Zahn TP, Keysor CS, Hamburger SD, et al. A 2-year prospective follow-up study of children and adolescents with disruptive behavior disorders. Prediction by cerebrospinal fluid 5-hydroxyindoleacetic acid, homovanillic acid, and autonomic measures? *Arch Gen Psychiatry*. 1992; 49:429–435. [PubMed: 1376104]
204. Parsey RV, Oquendo MA, Simpson NR, Ogden RT, Van Heertum R, et al. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. *Brain Res*. 2002; 954:173–182. [PubMed: 12414100]
205. Schulz KP, Newcorn JH, McKay KE, Himmelstein J, Koda VH, et al. Relationship between central serotonergic function and aggression prepubertal boys: effect of age and attention-deficit/hyperactivity disorder. *Psychiatry Res*. 2001; 101:1–10. [PubMed: 11223114]
206. Evenden JL. Varieties of impulsivity. *Psychopharmacology (Berl)*. 1999; 146:348–361. [PubMed: 10550486]
207. Posner MI, Rothbart MK. Attention, self-regulation and consciousness. *Philos Trans R Soc Lond B Biol Sci*. 1998; 353:1915–1927. [PubMed: 9854264]

208. Robinson ES, Eagle DM, Mar AC, Bari A, Banerjee G, et al. Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. *Neuropsychopharmacology*. 2008; 33:1028–1037. [PubMed: 17637611]
209. Sobanski E, Banaschewski T, Asherson P, Buitelaar J, Chen W, et al. Emotional lability in children and adolescents with attention deficit/hyperactivity disorder (ADHD): clinical correlates and familial prevalence. *J Child Psychol Psychiatry*. 2010; 51:915–923. [PubMed: 20132417]
210. Connor DF, Chartier KG, Preen EC, Kaplan RF. Impulsive aggression in attention-deficit/hyperactivity disorder: symptom severity, co-morbidity, and attention-deficit/hyperactivity disorder subtype. *J Child Adolesc Psychopharmacol*. 2010; 20:119–126. [PubMed: 20415607]
211. Doerfler LA, Connor DF, Toscano PF Jr. Aggression, ADHD symptoms, and dysphoria in children and adolescents diagnosed with bipolar disorder and ADHD. *J Affect Disord*. 2010; 131:312–319. [PubMed: 21168917]
212. Zepf FD. Attention-deficit/hyperactivity disorder and co-varying aggression - a relationship with serotonin-dependent impulsive and physiological trait moderators? *Acta Psychiatr Scand*. 2010; 121:81–83. [PubMed: 20059457]
213. Courtet P, Guillaume S, Malafosse A, Jollant F. Genes, suicide and decisions. *Eur Psychiatry*. 2010; 25:294–296. [PubMed: 20452189]
214. Wild-Wall N, Oades RD, Schmidt-Wessels M, Christiansen H, Falkenstein M. Neural activity associated with executive functions in adolescents with attention-deficit/hyperactivity disorder (ADHD). *Int J Psychophysiol*. 2009; 74:19–27. [PubMed: 19607863]
215. Hervey AS, Epstein JN, Curry JF. Neuropsychology of adults with attention-deficit/hyperactivity disorder: a meta-analytic review. *Neuropsychology*. 2004; 18:485–503. [PubMed: 15291727]
216. Sonuga-Barke EJ, Dalen L, Remington B. Do executive deficits and delay aversion make independent contributions to preschool attention-deficit/hyperactivity disorder symptoms? *J Am Acad Child Adolesc Psychiatry*. 2003; 42:1335–1342. [PubMed: 14566171]
217. Tseng MH, Henderson A, Chow SM, Yao G. Relationship between motor proficiency, attention, impulse, and activity in children with ADHD. *Dev Med Child Neurol*. 2004; 46:381–388. [PubMed: 15174529]
218. Carver CS, Johnson SL, Joormann J. Serotonergic function, two-mode models of self-regulation, and vulnerability to depression: what depression has in common with impulsive aggression. *Psychol Bull*. 2008; 134:912–943. [PubMed: 18954161]
219. Oades RD, Slusarek M, Velling S, Bondy B. Serotonin platelet-transporter measures in childhood attention-deficit/hyperactivity disorder (ADHD): clinical versus experimental measures of impulsivity. *World J Biol Psychiatry*. 2002; 3:96–100. [PubMed: 12479082]
220. Unis AS, Cook EH, Vincent JG, Gjerde DK, Perry BD, et al. Platelet serotonin measures in adolescents with conduct disorder. *Biol Psychiatry*. 1997; 42:553–559. [PubMed: 9376451]
221. Zepf FD, Holtmann M, Stadler C, Demisch L, Schmitt M, et al. Diminished serotonergic functioning in hostile children with ADHD: tryptophan depletion increases behavioural inhibition. *Pharmacopsychiatry*. 2008; 41:60–65. [PubMed: 18311686]
222. Zepf FD, Stadler C, Demisch L, Schmitt M, Landgraf M, et al. Serotonergic functioning and trait-impulsivity in attention-deficit/hyperactivity-disordered boys (ADHD): influence of rapid tryptophan depletion. *Hum Psychopharmacol*. 2008; 23:43–51. [PubMed: 17926336]
223. Oades RD, Lasky-Su J, Christiansen H, Faraone SV, Sonuga-Barke EJ, et al. The influence of serotonin- and other genes on impulsive behavioral aggression and cognitive impulsivity in children with attention-deficit/hyperactivity disorder (ADHD): Findings from a family-based association test (FBAT) analysis. *Behav Brain Funct*. 2008; 4:48. [PubMed: 18937842]
224. Salo J, Pulkki-Raback L, Hintsanen M, Lehtimäki T, Keltikangas-Jarvinen L. The interaction between serotonin receptor 2A and catechol-O-methyltransferase gene polymorphisms is associated with the novelty-seeking subscale impulsiveness. *Psychiatr Genet*. 2010; 20:273–281. [PubMed: 20431430]
225. Mobini S, Chiang TJ, Ho MY, Bradshaw CM, Szabadi E. Effects of central 5-hydroxytryptamine depletion on sensitivity to delayed and probabilistic reinforcement. *Psychopharmacology (Berl)*. 2000; 152:390–397. [PubMed: 11140331]

226. Rogers RD, Tunbridge EM, Bhagwagar Z, Drevets WC, Sahakian BJ, et al. Tryptophan depletion alters the decision-making of healthy volunteers through altered processing of reward cues. *Neuropsychopharmacology*. 2003; 28:153–162. [PubMed: 12496952]
227. Walderhaug E, Lunde H, Nordvik JE, Landro NI, Refsum H, et al. Lowering of serotonin by rapid tryptophan depletion increases impulsiveness in normal individuals. *Psychopharmacology (Berl)*. 2002; 164:385–391. [PubMed: 12457268]
228. Walderhaug E, Magnusson A, Neumeister A, Lappalainen J, Lunde H, et al. Interactive effects of sex and 5-HTTLPR on mood and impulsivity during tryptophan depletion in healthy people. *Biol Psychiatry*. 2007; 62:593–599. [PubMed: 17544379]
229. Murphy SE, Longhitano C, Ayres RE, Cowen PJ, Harmer CJ, et al. The role of serotonin in nonnormative risky choice: the effects of tryptophan supplements on the “reflection effect” in healthy adult volunteers. *J Cogn Neurosci*. 2009; 21:1709–1719. [PubMed: 18823228]
230. Rubia K, Lee F, Cleare AJ, Tunstall N, Fu CH, et al. Tryptophan depletion reduces right inferior prefrontal activation during response inhibition in fast, event-related fMRI. *Psychopharmacology (Berl)*. 2005; 179:791–803. [PubMed: 15887056]
231. Jollant F, Buresi C, Guillaume S, Jaussest I, Bellivier F, et al. The influence of four serotonin-related genes on decision-making in suicide attempters. *Am J Med Genet B Neuropsychiatr Genet*. 2007; 144B:615–624. [PubMed: 17221847]
232. Haghghi F, Bach-Mizrachi H, Huang YY, Arango V, Shi S, et al. Genetic architecture of the human tryptophan hydroxylase 2 Gene: existence of neural isoforms and relevance for major depression. *Mol Psychiatry*. 2008; 13:813–820. [PubMed: 18180764]
233. Lopez VA, Detera-Wadleigh S, Cardona I, Kassem L, McMahon FJ. Nested association between genetic variation in tryptophan hydroxylase II, bipolar affective disorder, and suicide attempts. *Biol Psychiatry*. 2007; 61:181–186. [PubMed: 16806105]
234. Zill P, Buttner A, Eisenmenger W, Moller HJ, Bondy B, et al. Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase Isoform (TPH2) gene in suicide victims. *Biological psychiatry*. 2004; 56:581–586. [PubMed: 15476687]
235. Zill P, Preuss UW, Koller G, Bondy B, Soyka M. SNP- and Haplotype Analysis of the Tryptophan Hydroxylase 2 Gene in Alcohol-Dependent Patients and Alcohol-Related Suicide. *Neuropsychopharmacology*. 2007; 32:1687–1694. [PubMed: 17251907]
236. Juhasz G, Downey D, Hinvest N, Thomas E, Chase D, et al. Risk-taking behavior in a gambling task associated with variations in the tryptophan hydroxylase 2 gene: relevance to psychiatric disorders. *Neuropsychopharmacology*. 2010; 35:1109–1119. [PubMed: 20043001]
237. Walderhaug E, Herman AI, Magnusson A, Morgan MJ, Landro NI. The short (S) allele of the serotonin transporter polymorphism and acute tryptophan depletion both increase impulsivity in men. *Neurosci Lett*. 2010; 473:208–211. [PubMed: 20188795]
238. Kinnally EL, Capitanio JP, Leibel R, Deng L, LeDuc C, et al. Epigenetic regulation of serotonin transporter expression and behavior in infant rhesus macaques. *Genes Brain Behav*. 2010; 9:575–582. [PubMed: 20398062]
239. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. *Science*. 2003; 301:386–389. [PubMed: 12869766]
240. Jacob CP, Nguyen TT, Dempfle A, Heine M, Windemuth-Kieselbach C, et al. *Eur Arch Psychiatry Clin Neurosci*. 2010; 260:317–326. [PubMed: 19894072]
241. Levy F. Dopamine vs noradrenaline: inverted-U effects and ADHD theories. *Australian and New Zealand Journal of Psychiatry*. 2009; 43:101–108. [PubMed: 19153917]
242. Bobb AJ, Addington AM, Sidransky E, Gornick MC, Lerch JP, et al. Support for association between ADHD and two candidate genes: NET1 and DRD1. *Am J Med Genet B Neuropsychiatr Genet*. 2005; 134B:67–72. [PubMed: 15717291]
243. Madras BK, Miller GM, Fischman AJ. The dopamine transporter and attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2005; 57:1397–1409. [PubMed: 15950014]
244. Yang LI, Wang Y-F, Li JUN, Faraone SV. Association of Norepinephrine Transporter Gene With Methylphenidate Response. *J Am Acad Child Adolesc Psychiatry*. 2004; 43:1154–1158. [PubMed: 15322419]

245. Bhaduri N, Mukhopadhyay K. Lack of significant association between-1021C-->T polymorphism in the dopamine beta hydroxylase gene and attention deficit hyperactivity disorder. *Neurosci Lett.* 2006; 402:12–16. [PubMed: 16616989]
246. McEvoy B, Hawi Z, Fitzgerald M, Gill M. No evidence of linkage or association between the norepinephrine transporter (NET) gene polymorphisms and ADHD in the Irish population. *Am J Med Genet.* 2002; 114:665–666. [PubMed: 12210284]
247. Barr CL, Kroft J, Feng Y, Wigg K, Roberts W, et al. The norepinephrine transporter gene and attention-deficit hyperactivity disorder. *Am J Med Genet.* 2002; 114:255–259. [PubMed: 11920844]
248. Roman T, Schmitz M, Polanczyk GV, Eizirik M, Rohde LA, et al. Further evidence for the association between attention-deficit/hyperactivity disorder and the dopamine-beta-hydroxylase gene. *Am J Med Genet.* 2002; 114:154–158. [PubMed: 11857576]
249. Hu YF, Caron MG, Sieber-Blum M. Norepinephrine transport-mediated gene expression in noradrenergic neurogenesis. *BMC Genomics.* 2009; 10:151. [PubMed: 19356247]
250. Kollins SH, Anastopoulos AD, Lachiewicz AM, FitzGerald D, Morrissey-Kane E, et al. SNPs in dopamine D2 receptor gene (DRD2) and norepinephrine transporter gene (NET) are associated with continuous performance task (CPT) phenotypes in ADHD children and their families. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B:1580–1588. [PubMed: 18821566]
251. Giesbrecht T, Geraerts E, Merckelbach H. Dissociation, memory commission errors, and heightened autonomic reactivity. *Psychiatry Res.* 2007; 150:277–285. [PubMed: 17324470]
252. Hess C, Reif A, Strobel A, Boreatti-Hummer A, Heine M, et al. A functional dopamine-beta-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders. *J Neural Transm.* 2009; 116:121–130. [PubMed: 18982239]
253. Kaplow JB, Hall E, Koenen KC, Dodge KA, Amaya-Jackson L. Dissociation predicts later attention problems in sexually abused children. *Child Abuse Negl.* 2008; 32:261–275. [PubMed: 18308391]
254. Rubia K, Halari R, Smith AB, Mohammed M, Scott S, et al. Dissociated functional brain abnormalities of inhibition in boys with pure conduct disorder and in boys with pure attention deficit hyperactivity disorder. *Am J Psychiatry.* 2008; 165:889–897. [PubMed: 18413706]
255. Rubia K, Smith AB, Halari R, Matsukura F, Mohammad M, et al. Disorder-specific dissociation of orbitofrontal dysfunction in boys with pure conduct disorder during reward and ventrolateral prefrontal dysfunction in boys with pure ADHD during sustained attention. *Am J Psychiatry.* 2009; 166:83–94. [PubMed: 18829871]
256. Soukup J, Papezova H, Kubena AA, Mikolajova V. Dissociation in non-clinical and clinical sample of Czech adolescents. Reliability and validity of the Czech version of the Adolescent Dissociative Experiences Scale. *Eur Psychiatry.* 2010; 25:390–395. [PubMed: 20646916]
257. Joung Y, Kim CH, Moon J, Jang WS, Yang J, et al. Association studies of -3081 (A/T) polymorphism of norepinephrine transporter gene with attention deficit/hyperactivity disorder in Korean population. *Am J Med Genet B Neuropsychiatr Genet.* 2010; 153B:691–694. [PubMed: 19685476]
258. Chase T, Carrey N, Soo E, Wilkinson M. Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum. *Neuroscience.* 2007; 144:969–984. [PubMed: 17156936]
259. Xu X, Mill J, Zhou K, Brookes K, Chen C-K, et al. Family-based association study between brain-derived neurotrophic factor gene polymorphisms and attention deficit hyperactivity disorder in UK and Taiwanese samples. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.* 2007; 144B:83–86.
260. Lang UE, Hellweg R, Sander T, Gallinat J. The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. *Mol Psychiatry.* 2009; 14:120–122. [PubMed: 19156154]
261. Friedel S, Horro FF, Wermter AK, Geller F, Dempfle A, et al. Mutation screen of the brain derived neurotrophic factor gene (BDNF): identification of several genetic variants and association studies in patients with obesity, eating disorders, and attention-deficit/hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet.* 2005; 132B:96–99. [PubMed: 15457498]

262. Schimmelmann BG, Friedel S, Dempfle A, Warnke A, Lesch KP, et al. No evidence for preferential transmission of common valine allele of the Val66Met polymorphism of the brain-derived neurotrophic factor gene (BDNF) in ADHD. *J Neural Transm.* 2007; 114:523–526. [PubMed: 17219016]
263. Drtilkova I, Sery O, Theiner P, Uhrova A, Zackova M, et al. Clinical and molecular-genetic markers of ADHD in children. *Neuro Endocrinol Lett.* 2008; 29:320–327. [PubMed: 18580852]
264. Lanktree M, Squassina A, Krinsky M, Strauss J, Jain U, et al. Association study of brain-derived neurotrophic factor (BDNF) and LIN-7 homolog (LIN-7) genes with adult attention-deficit/hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B:945–951. [PubMed: 18286632]
265. Lasky-Su J, Faraone SV, Lange C, Tsuang MT, Doyle AE, et al. A study of how socioeconomic status moderates the relationship between SNPs encompassing BDNF and ADHD symptom counts in ADHD families. *Behav Genet.* 2007; 37:487–497. [PubMed: 17216343]
266. Lee J, Laurin N, Crosbie J, Ickowicz A, Pathare T, et al. Association study of the brain-derived neurotrophic factor (BDNF) gene in attention deficit hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet.* 2007; 144B:976–981. [PubMed: 17918236]
267. Banaschewski T, Becker K, Scherag S, Franke B, Coghill D. Molecular genetics of attention-deficit/hyperactivity disorder: an overview. *Eur Child Adolesc Psychiatry.* 2010; 19:237–257. [PubMed: 20145962]
268. Sanchez-Mora C, Ribases M, Ramos-Quiroga JA, Casas M, Bosch R, et al. Meta-analysis of brain-derived neurotrophic factor p.Val66Met in adult ADHD in four European populations. *Am J Med Genet B Neuropsychiatr Genet.* 2009; 153B:512–523. [PubMed: 19603419]
269. Aureli A, Del Beato T, Sebastiani P, Marimpietri A, Melillo CV, et al. Attention-deficit hyperactivity disorder and intellectual disability: a study of association with brain-derived neurotrophic factor gene polymorphisms. *Int J Immunopathol Pharmacol.* 2010; 23:873–880. [PubMed: 20943059]
270. van Beijsterveldt CE, Middeldorp CM, Slof-Op't Landt MC, Bartels M, Hottenga JJ, et al. Influence of candidate genes on attention problems in children: a longitudinal study. *Behav Genet.* 2010; 41:155–164. [PubMed: 21049304]
271. Dresler T, Ehlis AC, Heinz S, Renner TJ, Reif A, et al. Dopamine transporter (SLC6A3) genotype impacts neurophysiological correlates of cognitive response control in an adult sample of patients with ADHD. *Neuropsychopharmacology.* 2010; 35:2193–2202. [PubMed: 20631685]
272. Cho SC, Kim JW, Kim HW, Kim BN, Shin MS, et al. Effect of ADRA2A and BDNF gene-gene interaction on the continuous performance test phenotype. *Psychiatr Genet.* 2010; 21:132–135. [PubMed: 21063237]
273. Ferrer M, Andion O, Matali J, Valero S, Navarro JA, et al. Comorbid attention-deficit/hyperactivity disorder in borderline patients defines an impulsive subtype of borderline personality disorder. *J Pers Disord.* 2010; 24:812–822. [PubMed: 21158602]
274. Martel MM, Gremillion M, Roberts B, von Eye A, Nigg JT. The structure of childhood disruptive behaviors. *Psychol Assess.* 2010; 22:816–826. [PubMed: 21133546]
275. Shuai L, Chan RC, Wang Y. Executive Function Profile of Chinese Boys with Attention-Deficit Hyperactivity Disorder: Different Subtypes and Comorbidity. *Arch Clin Neuropsychol.* 2010; 26:120–132. [PubMed: 21177762]
276. Lichtenstein P, Carlstrom E, Rastam M, Gillberg C, Anckarsater H. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. *Am J Psychiatry.* 2010; 167:1357–1363. [PubMed: 20686188]
277. Wood AC, Rijdsdijk F, Asherson P, Kuntsi J. Hyperactive-impulsive symptom scores and oppositional behaviours reflect alternate manifestations of a single liability. *Behav Genet.* 2009; 39:447–460. [PubMed: 19633943]
278. Young SE, Friedman NP, Miyake A, Willcutt EG, Corley RP, et al. Behavioral disinhibition: liability for externalizing spectrum disorders and its genetic and environmental relation to response inhibition across adolescence. *J Abnorm Psychol.* 2009; 118:117–130. [PubMed: 19222319]

279. Zhou K, Chen W, Buitelaar J, Banaschewski T, Oades RD, et al. Genetic heterogeneity in ADHD: DAT1 gene only affects probands without CD. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B:1481–1487. [PubMed: 18553640]
280. Qian QJ, Liu J, Wang YF, Yang L, Guan LL, et al. Attention Deficit Hyperactivity Disorder comorbid oppositional defiant disorder and its predominately inattentive type: evidence for an association with COMT but not MAOA in a Chinese sample. *Behav Brain Funct.* 2009; 5:8. [PubMed: 19228412]
281. Freitag CM, Rohde LA, Lempp T, Romanos M. Phenotypic and measurement influences on heritability estimates in childhood ADHD. *Eur Child Adolesc Psychiatry.* 2010; 19:311–323. [PubMed: 20213230]
282. Tuvblad C, Zheng M, Raine A, Baker LA. A common genetic factor explains the covariation among ADHD ODD and CD symptoms in 9–10 year old boys and girls. *J Abnorm Child Psychol.* 2009; 37:153–167. [PubMed: 19015975]
283. Liu J. Childhood externalizing behavior: theory and implications. *J Child Adolesc Psychiatr Nurs.* 2004; 17:93–103. [PubMed: 15535385]
284. Vanyukov MM, Maher BS, Devlin B, Kirillova GP, Kirisci L, et al. The MAOA promoter polymorphism, disruptive behavior disorders, and early onset substance use disorder: gene-environment interaction. *Psychiatr Genet.* 2007; 17:323–332. [PubMed: 18075472]
285. Ioannidis JP. Why most published research findings are false. *PLoS Med.* 2005; 2:e124. [PubMed: 16060722]
286. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. *Am J Psychiatry.* 1998; 155:1325–1331. [PubMed: 9766762]
287. Contini V, Victor MM, Marques FZ, Bertuzzi GP, Salgado CA, et al. Response to methylphenidate is not influenced by DAT1 polymorphisms in a sample of Brazilian adult patients with ADHD. *J Neural Transm.* 2010; 117:269–276. [PubMed: 20049490]
288. Genro JP, Polanczyk GV, Zeni C, Oliveira AS, Roman T, et al. A common haplotype at the dopamine transporter gene 5' region is associated with attention-deficit/hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B:1568–1575. [PubMed: 18802919]
289. Ouellet-Morin I, Wigg KG, Feng Y, Dionne G, Robaey P, et al. Association of the dopamine transporter gene and ADHD symptoms in a Canadian population-based sample of same-age twins. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B:1442–1449. [PubMed: 18165969]
290. Stein MA, Waldman ID, Sarampote CS, Seymour KE, Robb AS, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. *Neuropsychopharmacology.* 2005; 30:1374–1382. [PubMed: 15827573]
291. Thakur GA, Grizenko N, Sengupta SM, Schmitz N, Joobor R. The 5-HTTLPR polymorphism of the serotonin transporter gene and short term behavioral response to methylphenidate in children with ADHD. *BMC Psychiatry.* 2010; 10:50. [PubMed: 20569447]
292. Kereszturi E, Tarnok Z, Bogнар E, Lakatos K, Farkas L, et al. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. *Am J Med Genet B Neuropsychiatr Genet.* 2008; 147B:1431–1435. [PubMed: 18214865]
293. Leddy JJ, Waxmonsky JG, Salis RJ, Paluch RA, Gnagy EM, et al. Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths. *J Child Adolesc Psychopharmacol.* 2009; 19:127–136. [PubMed: 19364291]
294. Cheon KA, Kim BN, Cho SC. Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children. *Neuropsychopharmacology.* 2007; 32:1377–1383. [PubMed: 17077808]
295. Palmason H, Moser D, Sigmund J, Vogler C, Hanig S, et al. Attention-deficit/hyperactivity disorder phenotype is influenced by a functional catechol-O-methyltransferase variant. *J Neural Transm.* 2010; 117:259–267. [PubMed: 19946713]
296. Zalsman G, Patya M, Frisch A, Ofek H, Schapir L, et al. Association of polymorphisms of the serotonergic pathways with clinical traits of impulsive-aggression and suicidality in adolescents: A multi-center study. *World J Biol Psychiatry.* 2010; 12:33–41. [PubMed: 20873971]

297. Acosta MT, Arcos-Burgos M, Muenke M. Attention deficit/hyperactivity disorder (ADHD): complex phenotype, simple genotype? *Genet Med.* 2004; 6:1–15. [PubMed: 14726804]
298. Purper-Ouakil D, Lepagnol-Bestel AM, Grosbellet E, Gorwood P, Simonneau M. Neurobiology of attention deficit/hyperactivity disorder. *Med Sci (Paris).* 2010; 26:487–496. [PubMed: 20510147]
299. Bidwell LC, Willcutt EG, McQueen MB, Defries JC, Olson RK, et al. A Family Based Association Study of DRD4, DAT1, and 5HTT and Continuous Traits of Attention-Deficit Hyperactivity Disorder. *Behav Genet.* 2011; 41:165–174. [PubMed: 21207241]